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S U M M A R Y  
Summary 
RNA polymerase II (RNAP II) transiently associates with many different proteins 
and multiprotein complexes during the mRNA transcription cycle, which includes 
three phases, initiation, elongation, and termination. This thesis describes 
structural studies of two factors that facilitate transcription through chromatin. The 
heterodimeric Saccharomyces cerevisiae elongation factor Spt4-Spt5 (human DSIF) 
has been identified by biochemical and genetic approaches to help RNAP II 
transcribe through chromatin. It is assumed that Spt4-Spt5 pauses RNAP II to open 
a time window for capping enzyme recruitment and addition of a cap to the 5'-end 
of the nascent RNA. The preparation of milligram quantities of soluble Spt4-Spt5 
variants that are suited for structural studies has been achieved. Several strategies 
to resolve the structure of the RNAP II–Spt4-Spt5 complex were unsuccessful, 
possibly indicating an intrinsic flexibility of the complex. In addition, there is now 
evidence for direct links between chromatin modification and transcription 
elongation. A major player in this process is the histone lysine methyltransferase 
Set2 which has a modular structure. The catalytic activity of Set2 is mediated by 
the SET [Su(var)3-9, Enhancer of Zeste, Trithorax] domain. During mRNA 
elongation, the SRI (Set2 Rpb1-interacting) domain of Set2 binds to the 
phosphorylated CTD (carboxyl-terminal domain) of RNAP II. The NMR solution 
structure of yeast Set2 SRI domain has been determined. The structure reveals a 
novel CTD-binding fold consisting of a left-handed three-helix bundle. 
Unexpectedly, the SRI domain fold resembles the structure of an RNA polymerase-
interacting domain in σ factors that mediate transcription initiation in bacteria 
(domain σ2 in σ70). NMR titration experiments show that the SRI domain binds a 
Ser2/Ser5-phosphorylated CTD peptide comprising two heptapeptide repeats and 
three flanking NH2-terminal residues. Amino acid residues that show strong 
chemical shift perturbations upon CTD binding cluster in two regions on the SRI 
surface. The results will enable a detailed analysis of the specific CTD interactions 
underlying the coupling of transcription and chromatin modification by Set2.
 
Part of this work has been published 
Vojnic E., Simon B., Strahl B. D., Sattler M. and Cramer P. (2006) 
Structure and carboxyl-terminal domain (CTD) binding of the Set2 SRI domain that 
couples histone H3 Lys36 methylation to transcription. The Journal of Biological 
Chemistry. 281 (1), 13 – 15, Epub 2005 Nov 14. 
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Chapter I:  Introduction 
1 THE TRANSCRIPTION CYCLE 
The generation of mature mRNA molecules by eukaryotic RNA polymerase II 
(RNAP II = 12-subunit RNAP II), is a multistage process consisting of three major 
steps: initiation, elongation, and termination. Typically the transcription cycle starts 
with the binding of transcription factors and RNAP II to promoter sites and the 
onset of RNA synthesis by promoter clearance. During productive transcript 
elongation RNAP II moves along a protein-coding gene and synthesizes an mRNA 
copy. Finally, guided by DNA sequences at the end of a gene, RNAP II terminates 
transcription and releases newly synthesized mRNA. Mature mRNA is capped, 
cleaved, polyadenylated, and transported to the cytoplasm, where it is finally 
translated by ribosomes. Concomitantly, RNAP II is recycled and transcription 
reinitiation can occur [Figure 1; (reviewed by Sims 3rd et al., 2004; reviewed by 
Hahn, 2004)]. Although much has been learned about processes involved in 
initiation, much less is known regarding mechanisms that regulate later stages in 
the transcription process, particularly chain elongation. Therefore, great strides 
have been made to unveil mechanisms underlying transcription elongation, as it is 
one of the most important steps in the control of cell growth and differentiation. It 
is known, however, that the transition from transcriptional initiation to elongation is 
accompanied by a partial disassembly of the initiation complex and the recruitment 
of an elongation complex that consists of a different set of factors (Pokholok et al., 
2002). 
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Figure 1. The RNAP transcription cycle. The figure is taken from Hahn (2004).  
Transcription elongation at the level of chromatin is targeted by a multitude of 
transcription factors. Several lines of evidence led to the view that, in contrast to a 
simple linear assembly line, a complex and extensively coupled network has 
evolved to coordinate the activities of the gene expression machines (reviewed by 
Maniatis and Reed, 2002). Thus, the ultimate goal of understanding the regulation 
of gene expression in a physiological context will be achieved by taking into account 
the coordinated integration of basal transcriptional components, co-factors and 
chromatin. There are at least two key regulatory mechanisms that must occur 
during elongation. One is the maintenance of an 'open chromatin' structure so that 
RNAP II can traverse nucleosomes; the other is the organization of the capping, 
splicing, and polyadenylation reactions. Factors regulating transcript elongation on 
chromatin templates are represented by different classes of proteins: histone 
chaperones, ATP-dependent chromatin remodelers, histone-modifying enzymes, 
and topoisomerases (Reinberg and Sims 3rd, 2006). On the other hand, vast studies 
aimed at elucidating the cadre of elongation factors that either modulate the 
catalytic activity of RNAP II or serve to alleviate impediments to transcript 
elongation, including drug-induced or sequence dependent transcriptional pause 
and arrest. 
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2 STRUCTURE OF CHROMATIN IN TRANSCRIBED GENES 
2.1 The Histone Code - Nucleosomes as regulatory units 
In the nucleus of cells, chromatin represents the physiological state of DNA, where 
it is associated with histone and non-histone proteins. The basic building block of 
chromatin is the nucleosome, a structure consisting of an octamer of four core 
histone proteins around which 147 base pairs of DNA are wrapped. Histone proteins 
H2A, H2B, H3 and H4 are each composed of a structured globular domain and an 
unstructured tail domain (Luger et al., 1997). The amino termini of histones are 
highly accessible and experience numerous specific post-translational modifications. 
Especially residues of the amino termini of histones H3 and H4 and the amino and 
carboxyl termini of histones H2A, H2B and H1, are susceptible to an assortment of 
covalent alterations, including acetylation of lysines, methylation of lysines and 
arginines, phosphorylation of serines and threonines, ubiquitination of lysines, 
sumoylation of lysines, and the ADP-ribosylation of glutamic acids (Figure 2). The 
first three types of modifications have been studied extensively (Grunstein, 1997; 
reviewed by Nowak and Corces, 2004; reviewed by Martin and Zhang, 2005; 
Pokholok et al., 2005).  
These chromatin 'marks' are suggested to behave in a combinatorial manner 
defining a second code, the 'histone code', devoted to epigenetic regulation (Strahl 
and Allis, 2000; Jenuwein and Allis, 2001), thereby extending the information 
content of the genome past the genetic code. A systematic nomenclature for 
modified histones, termed the Brno nomenclature, tries to present the complex 
encoded information in a consistent and coherent manner (Turner, 2005). For 
instance, a triple methylation mark on lysine 4 of histone H3 is designated 
H3K4me3.  
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Figure 2. Posttranslational modifications of histones. The figure is created according 
Khorasanizadeh (2004). The 1AOI PDB entry (Luger et al., 1997) without DNA served as model and the 
color code is adapted from Rhodes (1997). 
However, the impact of certain modifications for specific nucleosome regulations 
has only emerged in the last decade or awaits discovery. Until recently, the 
methylation of histones appeared to be 'permanent' as nucleosomes were supposed 
to transmit epigenetic information from one cell generation to the next (reviewed 
by Bannister et al., 2002). In the absence of evidence for histone lysine 
demethylases, histone methylation has demonstrated the power of modifications 
over DNA-based functions, regulating fundamental processes such as gene 
transcription, DNA repair, and epigenetic inheritance (reviewed by Martin and 
Zhang, 2005; Huyen et al., 2004; Trojer and Reinberg, 2006; Vire et al., 2006). 
The recent identification of histone lysine demethylases raises now the question if 
the reversibility of histone lysine methyl marks jeopardizes their epigenetic status 
(Trojer and Reinberg, 2006). LSD1 (lysine-specific demethylase 1) displays 
stringent substrate specificity and demethylates mono- or di-methylated lysine K4 
within histone H3 using an amine oxidase reaction (Shi et al., 2004). LSD1 shows 
extensive sequence homology to metabolic FAD-dependent amine oxidases, but 
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additionally includes a nuclear localization signal (NLS) and a SWIRM (Swi3p, Rsc8p 
and Moira) domain that is often found in chromatin-associated proteins. The 
mechanism is not compatible with any tri-methylated lysine substrate, as especially 
a protonated nitrogen and FAD (flavin adenine dinucleotide) as cofactor are 
required. Recently, a crystal structure of human LSD1 revealed a centrally located, 
spacious active site cavity, which, however, does not confer the ability to determine 
the degree of methylation of the histone tail. The study rather approves that the 
chemical mechanism forms the basis for the enzyme's selectivity for mono- and di-
methylated substrates (Stavropoulos et al., 2006). This limitation and the caveat 
that a LSD1 homolog appears to be absent in Saccharomyces cerevisiae proposed 
that additional demethylases with an alternative reaction mechanism to reverse 
lysine methylation exist. This assumption was confirmed by the discovery of JmjC 
(jumonji domain C) domain containing proteins that comprise a new subfamily of 
the large oxygenase family. JHDM1 (JmjC domain containing histone demethylase 
1) is the first protein of this family that was shown to specifically act on di-
methylated lysine K36 within histone H3 (Tsukada et al., 2006). The 
Saccharomyces cerevisiae homolog scJHDM1 is a genuine H3K36me2 demethylase 
whereas recombinant Epe1, the Schizosaccharomyces pombe homologue, lacks 
histone demethylase activity (Tsukada et al., 2006; Trewick et al., 2005). Another 
approach showed that JMJD2A is a lysine tri-methyl-specific histone demethylase. 
This enzyme belongs to the JMJD2 subfamily of JmjC domain containing proteins 
and is evolutionarily conserved from Caenorhabditis elegans to human (Whetstine 
et al., 2006). The demethylase signature motif, the JmjC domain, reverses 
methylation in a radical-based oxidative manner (hydroxylation). This mechanism is 
chemically compatible with demethylation of trimethylated substrates and uses 
Fe(II) and α-ketoglutarate as cofactors. JMJD2A activity on both H3K9me3 and 
H3K36me3 results in di-methylated, but no mono- or unmethylated products.  
Despite the different mechanisms used to antagonize histone methylation, these 
results firmly establish that these marks are not static – rather as dynamic and 
versatile as the other histone modifications and that histone lysine demethylases 
offer a new spectrum how methylation influences chromatin, given the plethora of 
different methylation sites (reviewed by Mellor, 2006).  
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2.2 Histone methylation in transcriptional control 
Efficient elongation on chromatin necessitates the displacement of the physical 
barrier imposed by the nucleosome on the transcribing RNAP II (reviewed by 
Workmann, 2006). Histone methylation occurs on arginine and lysine residues and 
is catalyzed by enzymes belonging to three distinct families of proteins – the PRMT 
(protein arginine methyltransferase) family, the SET-domain-containing [Su(var)3-
9, Enhancer of Zeste, Trithorax] protein family, and the non-SET-domain proteins 
DOT1/DOT1L (disruptor of telomeric silencing-1). However, a methyl group is 
relatively small and its addition to lysine or arginine residues does not neutralize 
their charge, so it is unlikely that methylation alone will significantly affect 
chromatin structure. It is more likely that it serves as an anchorage point for the 
recruitment of regulatory proteins that contain specialized binding domains. Among 
the binding modules that have a high specificity for methylated histone residues are 
chromodomains, Tudor domains and WD40-repeats (Figure 3). For instance, the 
structure of the hybrid-tudor domains of JMJD2A bound to a tri-methylated H3K4 
peptide was reported recently (Huang et al., 2006). Moreover, chromatin 
immunoprecipitation and biochemical experiments show that the chromodomain of 
Eaf3 recruits the repressive histone deacetylase complex Rpd3C(S) to nucleosomes 
methylated by Set2 on H3K36. By generating a localized deacetylated template the 
nucleosomal organization is restored and aberrant transcription initiation is 
prevented (Carrozza et al., 2005; Keogh et al., 2005). Repressive proteins, such as 
HP1 (heterochromatin protein 1) or the Drosophila PC (Polycomb) protein, associate 
with methylated chromatin in a unique manner governed by their respective 
chromodomain, which is discriminatory for binding to the tri-methylated K9 and 
K27 within histone H3 (reviewed by Margueron et al., 2005). By contrast, the CHD1 
(chromodomain helicase DNA-binding protein 1) activator protein from human uses 
both chromodomains to recognize the activating tri-methylated K4 within histone 
H3 (Sims 3rd et al., 2005; Flanagan, 2005), whereas the same function for 
Saccharomyces cerevisiae is contested, albeit supporting results are on hand (Pray-
Grant et al., 2005; Sims 3rd et al., 2005). According to these examples, the 
ultimate function of the methyl epitope is a reflection of the type of protein it has 
evolved to recruit – either a repressor or an activator of transcription (Figure 3).  
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Figure 3. Histone lysine methyltransferases, their target sites and methyl-lysine binding 
domains. The figure is adapted from Martin and Zhang (2005). 
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Regarding lysine methylation, studies show that a number of lysines (K4, K9, K27, 
K36, and K79 of H3 and K20 of H4) are the major identified sites of methylation, 
although species-specific differences exist (reviewed by Sims 3rd et al., 2003). 
Methylation marks that are linked to open chromatin and transcriptional activation 
(preferentially H3K4-H3K36 and H3K79) are present in all eukaryotes. On the other 
hand, H3K9, H3K27 and H4K20 methylation are hallmarks of a condensed 
chromatin state, albeit not found in Saccharomyces cerevisiae (reviewed by Sims 
3rd et al., 2003). HKMTs (Histone lysine methyltransferases) can add up to three 
methyl groups to a single lysine, thereby extending the indexing potential of this 
particular modification. Generally, in lower eukaryotes all three degrees of labeling 
of a particular histone site are regulated by the same enzyme, whereas in higher 
eukaryotes histone lysine methyltransferases were identified that specifically 
transfer only one methyl epitope. To dissect the possible functional reason of 
different degrees of methylation within chromatin context, the identification of 
diverse histone methyltransferases was followed in quick succession by a number of 
crystal structures (Xiao et al., 2003; Zhang et al., 2003; Xiao et al., 2005). Unlike 
human Set1, Set7/9 acts as a H3K4 mono-methyltransferase. This intrinsic 
methylation product specificity is apparent from its crystal structure and the 
structural comparison with DIM-5, an H3K9me3 methyltransferase from Neurospora 
crassa. The lysine-access channel, a common feature of SET enzymes, connects the 
substrate- and cofactor-binding sites. In the process of subsequent methylation, 
the steric hindrance resulting from the increasing bulk of the lysine ε-amino group 
accounts for target and product specificity. In the case of Set7/9, it is speculated 
that the arrangement of a protein side chain may be the determinant for limited 
addition of methyl marks (Xiao et al., 2003). By comparison, the cavity at the 
active site of DIM-5 seems spacious enough to accommodate even a methyl moiety 
on the substrate (Zhang et al., 2003). Besides the given number of redundant 
HKMTs, further studies are needed to clarify even contradictory roles in 
transcription of H3K4 and H3K79. For example, H3K4 tri-methylation was found to 
be associated with the promoter and 5'-coding regions of exclusively active genes 
in yeast and higher eukaryotes, whereas H3K4 di-methylation appeared on active 
and inactive euchromatic genes in yeast (Santos-Rosa et al., 2002). Nevertheless, 
it is envisaged that these modification states evoke specialized downstream 
responses. 
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2.3 Dynamic nucleosomes and gene transcription 
Compacted chromatin must be rendered accessible for efficient RNAP II mediated 
gene expression. This process is amongst others, accomplished by a set of enzymes 
known as modifying complexes. Recent work gained insight into the impact of 
methylation profiles onto transcription processes, thus providing evidence for 
crosstalk between chromatin function and gene expression. The histone 
methyltransferases Set1 and Set2 (Figure 4 shows a summary of Set2), which 
modify the histone H3 lysines K4 and K36, respectively, are associated with 
RNAP II during elongation (reviewed by Gerber and Shilatifard, 2003; reviewed by 
Hampsey and Reinberg, 2003). Histone methylation apparently controls newly 
initiated RNAP II, and two phases of histone H3 methylation can be distinguished 
after transcription initiation (Morillon et al., 2005). Set1 is part of a larger complex 
termed COMPASS (Complex of proteins associated with Set1) and associates with 
newly initiated RNAP II when Ser5 of the CTD is phosphorylated whereas this 
interaction is mediated by the Paf1 complex (Ng et al., 2003). K4 and K79 
methylation by Set1 and Dot1, respectively, are coregulated by a preexisting mark 
on a different histone tail. Ubiquitination of K123 within histone H2B by Rad6 and 
Bre1 is the necessary prerequisite (Sun and Allis, 2002; Ng et al., 2002; Wood et 
al., 2003). Latest results suggest that H2B ubiquitylation is in fact dispensable for 
monomethylation of the histone tail but necessary to stimulate subsequent rounds 
of methylation (Shahbazian et al., 2005). By contrast, Set2 directly interacts with 
the phosphorylated CTD of RNAP II and is observed throughout the coding region of 
genes (Krogan et al., 2003; Strahl et al., 2002; Xiao et al., 2003). Set2 recruitment 
to RNAP II relies on preceding phosphorylation of serine 2 of the CTD heptapeptide 
motif. Extensive genetic and interaction studies corroborate the functional link 
between H3K36 methylation by Set2 and the known serine 2 kinases CTDK-I and 
Bur1 (Krogan et al., 2003; Xiao et al., 2003; Li et al., 2003; Chu et al., 2006). It is 
speculated that the kinases might stimulate different degrees of methylation (Chu 
et al., 2006). In addition, the cis-trans interconversion of proline 38 on histone H3 
by the proline isomerase Fpr4 is supposed to interact with H3K36 methylation by 
Set2. This novel, noncovalent histone modification affects in an antagonistic 
manner the transduction of the signature motif (tri-methylation) and thus the 
transition from basal to active transcription (Nelson et al., 2006). 
C H A P T E R  I :  I N T R O D U C T I O N  
14 
The interaction between Set2 and the RNAP II CTD is mediated by a novel SRI 
(Set2 Rpb1-interacting) domain (Kizer et al., 2005; Phatnani et al., 2004). The SRI 
domain of Saccharomyces cerevisiae comprises the COOH-terminal residues 619 –
718 of Set2 (Kizer et al., 2005). In vitro, the yeast Set2 SRI domain binds 
specifically and with high affinity to the CTD doubly phosphorylated at Ser2 and 
Ser5 (Kizer et al., 2005). In vivo, deletion of the Set2 SRI domain abolishes H3K36 
methylation and impairs transcription elongation, suggesting that the SRI domain is 
responsible for coupling transcription to histone methylation by Set2 (Kizer et al., 
2005).  
 
Figure 4. Summary of the capacity of Set2.  
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3 THE mRNA ASSEMBLY LINE 
3.1 The CTD code – Heptad repeats as assembly platform 
RNAP II shares many similarities at the sequence and structural levels with other 
multi-subunit RNA polymerases, but the carboxyl-terminal domain (CTD) of its 
largest subunit Rpb1 is an outstanding feature. It is a unique feature of RNAP II as 
it is not present in RNAP I or RNAP III or in bacterial or viral RNA polymerases 
(West and Corden, 1995 and reference therein) and this extraordinary CTD 
contributes through protein-protein interactions to the functional organization of the 
nucleus by mediating the association of differential transcription factors with 
RNAP II. The CTD contains a number of tandemly repeated heptapeptides (52 in 
mammals and 26 in yeast) with the consensus sequence Tyr1-Ser2-Pro3-Thr4-
Ser5-Pro6-Ser7 (YSPTSPS). These repeats provide a landing pad for 
macromolecular assemblies involved in transcription or interdependent mRNA 
processing events (reviewed by Hirose and Manley, 2000; Fong and Bentley, 2001). 
It is speculated that the CTD interacts dynamically with transcription factors at the 
appropriate time, respectively, rather than carrying all these components 
throughout the transcription cycle. The stage of transcription and thereby CTD 
recognition by specific processing factors is dependent on the phosphorylation 
pattern of the repeats, which varies during the transcription cycle. Although there 
are five potential phoshorylation sites in a heptad repeat (Tyr1, Ser2, Thr4, Ser5, 
and Ser7), mainly the CTD positions Ser2 and Ser5 (Zhang and Corden, 1991) 
undergo waves of phorsphorylation and dephosphorylation (Dahmus, 1996 and 
reference therein; Komarnitsky et al., 2000). By virtue of the concerted action of 
CTD kinases and phosphatases the level and pattern of phosphorylation is 
determined (reviewed by Meinhart et al., 2005). Both modifications within the 
recurring motif are independently essential for viability (West and Corden, 1995; 
Yuryev and Corden, 1996) and play discrete roles in transcription. ChIP data 
revealed that Ser5 becomes phosphorylated at promoter proximal regions during 
transcription initiation/early elongation (Komarnitsky et al., 2000) and recruits 
capping enzymes (McCracken et al., 1997b; Cho et al., 1997; Schroeder et al., 
2000). Phosphorylation of Ser2 increases towards the 3'-end of the gene, where the 
level of Ser5 phosphorylation decreases (Schroeder et al., 2000; Cho et al., 2001), 
thereby recruiting the mRNA processing, polyadenylation and termination factors to 
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elongating RNAP II (McCracken et al., 1997a; reviewed by Proudfoot et al., 2002; 
Ahn et al., 2004). Additionally, the wide diversity of binding sites can be augmented 
when the cis-trans interconversion of peptide bonds N-terminal of prolines is 
considered. Pin1, a peptidyl-prolyl isomerase, and its homolog in Saccharomyces 
cerevisiae Ess1p specifically act at prolines that are preceded by phosphoserine and 
phosphothreonine (Hani et al., 1999; Lu et al., 1999). Both are implicated in the 
regulation of the CTD via their WW domain (Morris et al., 1999; Xu et al., 2003). 
This series of different phosphorylation patterns and conformation changes 
generates a 'CTD code' that determines fine-tuned configurations specific for 
binding of particular factors in the transcription cycle [Figure 5; (Buratowski, 
2003)].  
 
Figure 5. The CTD code – 16 possible configurations. The figure is adapted from Buratowski (2003). 
Possible phosphorylation sites are denoted by circled P (phosphor serine 2 red; phosphor serine 5 blue). 
Two prolines can adopt either the cis or trans configuration.  
3.2 Induced fit – CTD recognition pattern 
The apparent simplicity of the RNAP II CTD heptad repeats is deceptive as the 
structure of the CTD has been proven to be difficult to establish. The CTD appears 
as a tail-like extension protruding from the catalytic core of RNAP II, and is flexibly 
connected by a linker to a region near the RNA exit channel of the enzyme. 
Because of their largely disordered nature, neither the heptad repeats nor the linker 
are visible in the crystal structures of yeast RNAP II (Cramer et al., 2001; Armache 
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et al., 2003). Solution studies of unbound CTD peptides indicate that the free CTD 
is structurally plastic, although it shows some residual structure and a propensity to 
form β-turns (reviewed by Meinhart et al., 2005). In essence, an 'induced fit' 
mechanism is proposed, allowing the CTD to interact with multiple structurally 
dissimilar partners. Significant advancements in understanding CTD information 
content have been made by three crystal structures of CTD binding domains in 
conjunction with synthetic peptides. The structure of a doubly phosphorylated 
peptide, representing a single heptad repeat with phosphate moieties on Ser2 and 
Ser5 that is bound to the WW domain of Pin1 has been solved. This analysis 
revealed that the CTD peptide binds as an extended coil, projecting every third 
residue onto a unique face of the coil and with both phosphoserine-proline peptide 
bonds strictly in the trans configuration. Additionally, the phosphorylated residues 
form hydrogen bonds with Pin1 (Verdecia et al., 2000). Another approach 
demonstrated how four heptad repeats adopt a different conformation when bound 
to the guanylyltransferase Cgt1. In this case all Ser-5 where phosphorylated (Ser5-
P) and although only 17 amino acids were visible in the crystal structure, it was 
clearly shown how the CTD molds itself to this binding partner. The CTD repeats are 
bound to an extended surface of Cgt1, anchored at both ends by electrostatic 
interactions with Ser5-P and with extensive van der Waals contacts between Cgt1 
and CTD residues (Fabrega et al., 2003). The fact that RNAP I and RNAP III 
transcripts are not capped has been attributed to the lack of the CTD in those 
polymerases (Neugebauer and Roth; 1997; McCracken et al., 1997b). In the case 
of RNAP II, CTD phosphorylation is required for recruitment of capping enzymes to 
sites of transcription in vivo (Komarnitsky et al., 2000; Schroeder et al., 2000) and 
the Cgt1-CTD peptide complex reveals some of the interactions necessary for 
selective and efficient mRNA biogenesis. A third study showed that proteins are 
capable of recognizing CTD phosphorylation patterns indirectly. Phosphorylation at 
serine 2 is a hallmark for transcription elongation and triggers the recruitment of 
factors involved in subsequent processing of the 3'-end of mRNA (Ahn et al., 2004; 
Bird et al., 2004; Meinhart and Cramer, 2004). Several RNA-processing factors 
interact with RNAP II through a conserved CID domain (CTD-interacting domain) 
(Yuryev et al., 1996; Barilla et al., 2000). The structure of CID of yeast Pcf11, an 
essential protein involved in pre-mRNA 3'-end processing and transcription 
termination (Amrani et al., 1997), bound to Ser2-phosphorylated CTD peptide was 
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solved by X-ray crystallography. The central CTD motif Ser2-Pro3-Thr4-Ser5 forms 
a β-turn, whereas the flanking residues are in an extended conformation. The Ser2 
phospho-group points away from the CID surface and may contribute to the β-turn 
with an additional hydrogen bond. This stabilization seems to be important for the 
indirect recognition of the phosphorylated peptide (Meinhart and Cramer, 2004). 
The instructive findings of theses studies are that the phosphorylation array 
encodes information about the state of the transcriptional apparatus that can be 
conveyed to factors specialized in recognizing entirely different positional cues in 
the CTD primary and secondary structure.  
In addition, BRCT domains and FF domains are also known to interact via the C-
terminus of Rpb1 with RNAP II. Until now there is no structural information of these 
domains in combination with the CTD. 
3.3 FACT and Spt elongation factors 
3.3.1 FACT 
Intensive work has demonstrated that DNA accessibility is highly restrictive when 
assembled into chromatin and that eukaryotes have evolved elaborate mechanisms 
to both utilize and overcome this barrier to regulate and facilitate gene 
transcription. In vivo, RNAP II elongates through nucleosomes at a rate of 25 
nucleotides per second (Izban and Luse, 1992). In vitro, a similar transcriptional 
competence can only be achieved on naked DNA templates. This discrepancy 
pinpointed to the assumption that under physiological conditions cellular factors are 
assuring efficient transcription within the repressive context of nucleosomes. A 
biochemical complementation assay was established and succeeded in the 
identification of an evolutionarily conserved heterodimer that stimulates the 
progression of RNAP II through nucleosomal templates. This activity from HeLa 
nuclear extracts was named FACT (Facilitates Chromatin Transcription) (Orphanides 
et al., 1998). Further biochemical studies have shown that FACT specifically 
removes one H2A/H2B dimer from the nucleosome, thus disrupting its structure to 
allow RNAP II passage (Orphanides et al., 1998; Belotserkovskaya et al., 2003). In 
addition, FACT was found to possess intrinsic histone chaperone activity 
(Belotserkovskaya et al., 2003). Additionally, Chd1, a chromodomain-containing 
ATPase, physically associates with FACT (Krogan et al., 2002). Collectively, these 
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features of FACT maintain chromatin integrity in the wake of transcribing RNAP II, 
as disrupted chromatin structure becomes re-established during transcription. 
Besides its role in chromatin modulation, a capacity of FACT in transcript elongation 
was simultaneously established. Spt16 genetically interacts with the known 
elongation factors TFIIS, Spt4/5, Spt6, and the PAF complex (Orphanides et al., 
1999; Squazzo et al., 2002; Lindstrom et al., 2003). FACT functions in conjunction 
with P-TEFb to ameliorate DSIF/NELF-mediated inhibition of transcriptional 
elongation on naked DNA templates (Wada et al., 2000). FACT travels with 
elongating RNAP II at transcriptionally active genes in vivo and prevents 
transcriptional initiation from cryptic promoters (Mason and Struhl, 2003). A similar 
observation is made in Drosophila, where FACT and the RNAP II elongation complex 
colocalize along hsp70 (Saunders et al., 2003). FACT is intimately involved in the 
maintenance of chromatin structure and plays a prominent role in transcription 
elongation (reviewed by Reinberg and Sims 3rd, 2006).  
In human cells, hSPT16 and SSRP1 comprise this chromatin specific complex 
(Orphanides et al., 1999). The yeast counterparts, Spt16/Cdc68 and Pob3, were 
previously characterized as members of a CP complex that interacts specifically 
with DNA polymerase alpha (Wittmeyer et al., 1997; Brewster et al., 1998). 
However, the complex does not possess nucleosome binding capability as Pob3 
lacks a DNA-binding motif (Wittmeyer et al., 1997). This HMG (high-mobility group) 
box domain is found in the C-terminal part of SSRP1. The chromatin binding activity 
is provided by another protein named Nhp6. Therefore, Nhp6 and Pob3, structurally 
analogous to different domains of the vertebrate SSRP1 protein, function as a 
bipartite yeast analog of SSRP1 (Brewster et al., 2001; Formosa et al., 2001). The 
gene encoding the larger subunit of FACT, Spt16 belongs to the histone group of 
SPT genes.  
3.3.2 SPT genes  
SPT (Suppressor of Ty) genes were identified in Saccaromyces cerevisiae by 
selection for genetic suppressors of certain promoter insertion mutations (Winston 
et al., 1984). Under these conditions, transcription initiates from the inserted 
promoter, while the adjacent proper gene promoter is inhibited. This elegant 
genetic screen uncovered transcription factor mutations that offset the detrimental 
effects of inserting a foreign piece of DNA (a TY transposon element or its long-
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terminal-repeat δ) in the promoter of a reporter gene. Hence, all SPT gene 
mutations examined, showed reduced transcription initiation from Ty or δ, and 
conversely, normal transcription of the adjacent gene was restored. These results 
led to the view that they define factors with fundamental roles in transcription. As 
mentioned above, SPT16 belongs to a certain class of SPT genes, the histone class, 
which comprises additionally SPT4, SPT5 and SPT6 as well as SPT11 and SPT12, 
which encode histones H2A and H2B. Aside from the functions discussed, recent 
data from various groups suggest that Spt proteins may also function in other 
processes. For example Spt4 might play a role in transcription-coupled DNA repair 
(Jansen et al., 2000). However, I will focus on their influence upon transcription 
elongation.  
3.3.3 Spt6 
A confluence of biochemical and genetic approaches has identified Spt6, a 
conserved protein implicated in both transcription elongation and chromatin 
structure, to help RNAP II to transcribe through chromatin. Spt6 is essential and it 
was shown that it has an ATP-independent histone chaperone activity to promote 
nucleosome assembly by binding to histones H3 and H4 in vitro and in vivo (Bortvin 
and Winston, 1996). Recent work characterized that a spt6 mutation impairs the 
integrity of chromatin in active genes and permits aberrant transcription initiation 
from within the coding region of the constitutively active FLO8 gene (Kaplan et al., 
2003). Additionally, Spt6 appears to function as a factor that mediates nucleosome 
reassembly onto the PHO5, PHO8, ADH2, ADY2 and SUC2 promoters and that this 
unique function in rebuilding nucleosomes at promoters is essential for 
transcriptional repression (Adkins and Tyler, 2006). These recent results implicate 
Spt6 as a maintenance factor for chromatin structure in the wake of RNAP II 
transcript elongation and reveal some of its mechanistic properties.  
Another established supposition is that Spt6 acts as a modulator of RNAP II activity 
during elongation. Spt6 colocalizes with elongating RNAP II and Spt5 on actively 
transcribed genes in yeast (Krogan et al., 2002) and human (Endoh et al., 2004), 
as well as it is recruited throughout the transcription unit of heat shock genes in 
flies (Andrulis et al., 2000; Kaplan et al., 2000), albeit the physical interaction 
between Spt6 and Spt5 is weak. Classical elongation assays on naked DNA 
templates revealed that Spt6 functions as an elongation factor that enhances the 
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rate of transcription elongation of RNAP II both autonomously and together with 
DSIF (human Spt4-Spt5) in HeLa cells (Endoh et al., 2004). Consistent with the 
idea that Spt6 may be required for transcription elongation, it genetically interacts 
with TFIIS and shares one salient mutant phenotype. Mutants of both proteins are 
sensitive to the drug 6-azauracil (6-AU), which is a common indication for factors 
involved in this highly regulated multi-enzymatic process (Hartzog et al., 1998).  
3.3.4 Spt4/Spt5 
Several lines of evidence suggest that the Spt4-Spt5 complex exhibits several 
attributes implicated in chromatin modulation and transcript elongation (reviewed 
by Lindstrom et al., 2002 and Sims 3rd et al., 2004). First, DSIF [DRB (5,6-
dichloro-1-β-D-ribofuranosylbenzimidazole)-sensitivity-inducing factor] was isolated 
from HeLa cell nuclear extracts based on its ability to confer DRB sensitivity to a 
reconstituted in vitro transcription system. This evolutionarily conserved 
heterodimeric complex is composed of p160 (hSpt5) and p14 (hSpt4), which are 
the human homologs of Saccharomyces cerevisiae Spt5 and Spt4 (Wada et al., 
1998a; Hartzog et al., 1998). Spt5/DSIF p160 interacts preferentially with RNAP IIa 
via repeated domains in Spt5, termed KOW-motifs (Figure 6) that are homologous 
to the Escherichia coli transcription elongation factor NusG (Wada et al., 1998a; 
Wada et al., 1998b; Hartzog et al., 1998; Yamaguchi et al., 1999). Actually, 
additional experiments led to the conclusion that the phosphorylation pattern of the 
CTD determines RNAP II-DSIF interaction and that CTD phosphorylation releases 
p160 from RNAP II (Wada, 1998b; Lindstrom and Hartzog, 2001). Spt5 is essential 
for cell viability, whereas Spt4 is not. Genetic studies in yeast, in vitro transcription 
assays and ChIP experiments implicate Spt4 as a positive elongation factor with the 
capacity to antagonize the negative effects of RNAP II pausing imposed by the 
chromatin-remodeling yeast factor Isw1p (Morillon et al., 2003; Rondon et al., 
2004). Moreover, a bioinformatical approach identified Spt4 as the orthologue of 
archaeal (Methanococcus jannaschii) DNA-directed RNA polymerase subunit E" 
(Ponting 2002). The same study gauged the role of the N-terminal protein segment 
of Spt5, thereby revealing an additional significant similarity with NusG. Besides the 
known KOW motifs, Spt5 shares a novel NGN (NusG N-terminal) domain with NusG 
homologues in archaea, bacteria and eukarya. Both the NGN-domain and a protein 
segment comprising more than the first KOW-motif are mandatory for Spt4 binding 
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(Ivanov et al., 2000). A first insight in these evolutionary conserved domains was 
accomplished by the crystal structure of NusG from Aquifex aelicus. In addition, a 
model for the NGN- and KOW-domain of Escherichia coli NusG was the outcome of 
this study (Steiner et al., 2002). Another bioinformatic elaboration predicts that 
Spt5 adopts an SH3 domain-like fold and assumes that the binding to RNAP II 
occurs via the OB-fold of its subunit Rpb7 (Aloy et al., 2004). Spt5 plays in 
conjunction with Tat a distinct role in HIV-1 transcription by promoting the stability 
of transcription complexes at terminator sequences and minimizing the amount of 
polymerase pausing at arrest sites (Bourgeois et al., 2002). Spt4 and Spt5 display 
an extensive set of genetic and physical interactions with TFIIF, TFIIS, and Rad26 
as well as factors affecting chromatin structure like Spt6, FACT, Chd1, and the Paf1 
complex (Orphanides et al., 1999; Costa and Arndt, 2000; Jansen et al., 2000; 
Krogan et al., 2002; Squazzo et al., 2002; Lindstrom et al., 2003; Simic et al., 
2003; Endoh et al., 2004). Extensive studies involving Drosophila melanogaster 
depicted the distribution of Spt5 and Spt6 on polytene chromosomes. The fruit fly 
homologs colocalize with the hyperphosphorylated, elongating form of RNAP II at 
sites of active transcription (Andrulis et al., 2000, Kaplan et al., 2000). Spt5 may 
experience methylation at arginine residues by PRMT1 and PRMT5 in vitro. It is 
proposed that methylation of Spt5 together with P-TEFb-mediated phosphorylation 
of Spt5 and the CTD of RNAP II generates modifications which function in 
modulating their transcriptional elongation properties (Kwak et al., 2003). In 
addition, Spt5 interacts with factors associated with mRNA maturation and 
surveillance (Wen and Shatkin, 1999; Andrulis et al., 2002; Pei and Shuman 2002; 
Lindstrom et al., 2003). Latest results implicate Spt4-Spt5 in transcription 
elongation by RNAP I and rRNA processing (Schneider et al., 2006). 
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Figure 6. Domain architecture of Spt5. 
Conclusively, increasing lines of evidence showed that Spt4-Spt5 function depends 
on the CTD and CTD modifying enzymes like diverse CTD kinases and Fcp1, the 
major phosphatase (Lindstrom and Hartzog, 2001). In addition, it appeared that 
the partially purified factors used in the DRB sensitivity assay to identify DSIF 
contained an additional factor, termed negative elongation factor (NELF), which 
acts in cooperation with DSIF to inhibit elongation (Yamaguchi et al., 1999b). 
Notwithstanding the fact that NELF is still not identified in yeast and that the two 
kinase complexes Bur1/Bur2 and CTDK-I (Ctk1, 2 and 3) appear to functionally 
reconstitute the activity of the human cyclin-Cdk complex P-TEFb in yeast, a model 
evolved how DSIF acts as transcription elongation factor. In general, many 
eukaryotic elongation factors exert their role by either preventing or overcoming 
RNAP II transcriptional pausing. In the case of DSIF, the heterodimeric factor plays 
a pivotal role in the temporal coordination of capping and transcriptional elongation. 
The model states that DSIF binds to RNAP II shortly after initiation or during 
formation of the transcription complex at the promoter (Wada et al., 1998a; 
1998b) and subsequently recruits NELF, trapping the transcription machinery at 
promoter proximal sites [Figure 7; (Yamaguchi et al., 1999b)]. This pausing is 
elicited by NELF only in the presence of DSIF. Between initiation and arrest, the 
Cdk7 subunit of the general transcription factor TFIIH phosphorylates the CTD of 
RNAP II on serine 5 of its heptapeptide repeat. The paused RNAP II is then joined 
by the capping enzymes through stimulated interactions with the serine 5-modified 
CTD and DSIF (Pei and Shuman, 2002). DSIF/NELF mediated pausing allows a time 
frame for the capping enzyme recruitment and the faithful addition of a cap to the 
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5'-end of the nascent RNA ensures that RNAP II commits to productive elongation 
only after the transcript has been capped. Following the placement of the 7-
methylguanosine cap on pre-mRNA, P-TEFb binds to RNAP II and its activation 
triggers phosphorylation of serine 2 and the CTR (C-terminal region) of DSIF. This 
abrogates the repressive action of NELF/DSIF and subsequent reactivates RNAP II 
to synthesize functional mRNA precursors. Thus, P-TEFb and DSIF act 
antagonistically (Wada et al., 1998b). Latest results suggest that the threonines in 
the CTR of Spt5, a putative mini-CTD, are phosphorylated by P-TEFb (Yamada et 
al., 2006). This event serves as a regulatory switch, converting the 
unphosphorylated 'repressive' Spt5 into a phosphorylated 'stimulating' elongation 
factor (Yamada et al., 2006). DSIF's attributive opposing role in transcription 
elongation is thereby reflected (Wada et al., 1998a). These regulatory interactions 
that pause early transcription appear to have evolved to allow the assembly of 
mRNA maturation factors on the RNAP II CTD under conditions in which the 
polymerase is engaged in a productive transcription complex. This would be 
comparable with the 'checkpoints' that operate during the cell cycle to ensure that 
each phase of the cycle is complete before the next begins (reviewed by 
Orphanides and Reinberg, 2002). 
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Figure 7. The elongation checkpoint model. The figure is adapted from Orphanides and Reinberg 
(2002).
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4 THIS STUDY 
With nearly 60 subunits and a mass in excess of 3 million Daltons, the RNAP II 
transcription machinery poses a formidable challenge for structural analysis. The 
successful structure determination of the polymerase was the major breakthrough 
because it revealed the platform upon which all macromolecular components are 
assembled. The full biological significance of the RNAP II structure lies in the 
implications for the higher complexes formed with a plethora of transcription factors 
(Boeger et al., 2005). Against this backdrop, the central aim of this study was to 
elucidate the atomic structure of components of the transcription elongation 
machinery to highlight important missing details. A structural perspective on the 
system should allow us to move towards a molecular picture of this central nuclear 
process. A heterodimeric complex comprising Spt4 and Spt5 plays a pivotal role in 
transcription elongation. A part of this study is concerned with the interaction 
between this elongation factor and RNAP II. I describe here the design and 
synthesis of Spt4-Spt5 variants. Investigations of the binding to the RNAP II 
surface could be undertaken by constructing complexes from their component 
parts. The quest for structural analysis of this interaction has involved X-ray 
crystallographic methods. Recently, it emerged that transcription is also coupled to 
the alteration of chromatin structure and the biochemical well-documented histone 
lysine methyltransferase Set2 has the potential to influence both processes. I tried 
to capture specific molecular details of the interaction between RNAP II and the SRI 
(Set2 Rpb1-interacting) domain of Set2. A move in this direction has been 
attempted by solving the structure of this domain by NMR spectroscopy. Three α-
helices are arranged in a left-handed bundle and adopt a new fold which is capable 
to bind to RNAP II. In order to illuminate the understanding of the interplay among 
the CTD (C-terminal domain) and the SRI domain, my study involved both attempts 
of co-crystallizing CTD peptides with SRI variants and NMR titration experiments.  
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Chapter II:  Results and Discussion 
5 RECOMBINANT SPT4-SPT5 PROTEINS AND ASSEMBLY 
OF THE ELONGATION CHECKPOINT COMPLEX 
The successful addition of a cap to the 5'-end of the nascent RNA shortly after 
transcription initiation is reflected by the fact that RNAP II commits to productive 
elongation. To foster an expanded view of the cellular function of the heterodimeric 
elongation factor Spt4-Spt5, several endeavors have been made to predict and 
model the structure of interacting proteins, which combined create the so called 
'checkpoint elongation complex' (reviewed by Orphanides and Reinberg, 2002). The 
resulting structure should identify the interacting surfaces and nature of the 
protein-protein interaction.  
Before I started my project, great strides have been made to obtain endogenous 
RNAP II of high quality as the purification protocol of ten-subunit RNAP II had 
already proofed itself. The material used in this study was obtained as explicitly 
described elsewhere (see PhD-thesis Armache, 2005). In addition, I could adopt the 
experimental setup of synthetic DNA/RNA scaffolds used by H. Kettenberger in the 
laboratory (see PhD-thesis Kettenberger, 2005). During this thesis, the 
establishment of the 200 litres large scale fermentation to meet the growing 
demand for RNAP II, particularly with regard to illuminate the role of Spt4-Spt5 as 
transcription elongation factor, posed a challenge.  
I describe here the design and production of heterologous Spt4-Spt5 protein 
variants, and investigations of their binding to ten- or 12-subunit RNAP II. To 
unravel these interactions I availed myself of protein crystallography. In Table 1 the 
crystallization conditions used for this approach are summarized. They are slightly 
adjusted to the demands of the 'checkpoint elongation complex' and therefore differ 
from previously used reservoir solutions (see PhD-thesis Kettenberger, 2005). 
Finally, the cryo-protectant solutions contained the same components as the 
reservoir solutions plus 22 % of glycerol. Screening with increasing amounts of 
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cryo-protectants like MPD, PEG-400, PEG-600 or ethylenglycol could not rectify the 
established freezing procedure.  
Table 1: Summary of RNAP II crystallization conditions  
(reservoir solution) 
Citrate/PEG 11 – 14 % PEG-6000; 170 mM Tri-Sodium Citrate;  
100 mM Hepes pH 7.5; 5 mM DTT. 
Natrix #38 
modified 
4 – 5.5 % PEG-6000; 200 mM Ammonium Acetate;  
150 mM Magnesium acetate; 50 mM Hepes pH 7.5;  
5 mM DTT. 
(NH4)NaTartrate 750 – 825 mM Ammonium Sodium Tartrate;  
50 mM Hepes pH 7.5; 5 mM DTT. 
(NH4)NaTartrate/ 
PEG/KSCN 
12 – 14 % PEG-6000; 300 mM Ammonium Sodium 
Tartrate; 100 mM Hepes pH 7.5; 100 mM Potassium 
Thiocyanate; 5 mM DTT. 
MES 18 – 22 % Ammonium Sulfate; 50 mM MES pH 5.7;  
100 μm Zinc Chloride; 5 mM DTT. 
PEG/PO4 12 – 18 % PEG-6000; 390 Ammonium Sodium Phosphate  
pH 6.0; 50 mM Dioxane; 5 mM DTT. 
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5.1 Spt4-Spt5 bicistronic expression  
The production of constructs of Spt4 and Spt5 when expressed both separately and 
in combination, should allow analysis of their interaction with RNAP II. The rational 
behind the finally selected bicistronic expression strategy was to study a Spt5 
variant comprising the homologous NGN- and KOW1-domain of which the Aquifex 
aelicus crystal structure (Steiner et al., 2002) was identified and four additional 
KOW domains. Production of short Spt5 variants was feasible, but concomitantly 
accomplished experiments gave the hint that extended Spt5 variants could not be 
expressed. Only moderate expression levels were obtained. In addition, 
degradation products were already visible during the first purification step with Ni-
NTA affinity column. Insufficient results were obtained as soon as the Spt5 variants 
comprised the whole Spt4 binding region. Expression of these recombinant proteins 
in Escherichia coli seemed to be impaired, apparently due to a loss of structural 
integrity of Spt5 when expressed without Spt4. As this approach was 
unsatisfactory, the full length binding partner Spt4 was expected to stabilize the 
heterodimeric complex. Bicistronic expression offers the advantage of both placing 
two protein-coding sequences under the control of the same transcriptional 
regulation and facilitating co-translational folding of protein pairs.  
5.1.1 Purification of Spt4-Spt5 variant3 
Initially, a bicistronic expression vector was constructed containing an N-terminal 
GST-tag linked to Spt4 and a six-histidine-tag (His6-tag) introduced at the C-
terminus of a designed Spt5 variant. This variant3 encompasses all modular 
domains of wild type Spt5 disregarding the predicted unstructured segments found 
at the far end of the protein, exactly amino acid residues 283 to 849. Equivalent 
transcript levels of both proteins should be ensured by a purification protocol which 
makes successive use of both the GST- and the histidine affinity tag. But it turned 
out that the purification of the protein pair was not straightforward and for 
improved handling the GST-tag was removed from Spt4. The stoichiometry should 
be assured with downstream purification procedures. A two-step strategy was 
established which allowed the purification of a Spt4-Spt5 complex with an 
approximately 1:1 stoichiometry. The presence of Spt4 in the complex was verified 
by Edman-Sequencing. The last step was also performed by a Superose6 gel 
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filtration column. In doing so, the complex showed an aberrant retention volume, 
which could only be explained by inconvenient interactions with the column matrix. 
Before adjusting the size exclusion buffer to 100 mM ammonium sulphate, 
extensive screening of conditions was performed.  
5.1.2 Assembly of RNAP II with Spt4-Spt5 variant3 
The assembly reaction between Spt4-Spt5 and RNAP II was performed at 4 °C and 
the complex subsequently subjected to gel filtration. Finally, 35 μl of the peak 
fractions were mixed with sample buffer and the result of the size exclusion column 
monitored on a Coomassie stained SDS-polyacrylamid gel (Figure 8). Spt4 is not 
visible on the gel according to its small size of 11.2 kDa. But in consideration of the 
fact that independently expressed Spt5 variant3 is heavily degraded and that the 
Spt4-Spt5 variant3 complex was used for the experiment, I could show the 
interaction between the recombinant expressed proteins and RNAP II for the fist 
time by size exclusion chromatography.  
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Figure 8. Assembly of RNAP II with Spt4-Spt5. The chromatogram depicts the gel filtration profile of 
the assembly. The elution volume of approximately 13 ml corresponds to RNAP II. The excess of 
recombinant proteins elutes at approximately 16 ml and 21 ml, respectively. The Coomassie stained 
SDS-PAGE analysis demonstrates the purity of the final sample as obtained from the gel filtration. In 
addition, the inset shows the silver-staining of peak1 to highlight Rpb4 which is faintly visible with 
Coomassie. Neither the RNAP II subunits Rpb10 and Rpb12 nor Spt4 is visible due to their small size.  
Nevertheless, the production of sufficient quantities of the Spt4-Spt5 variant3 
complex was the bottleneck of this approach. Albeit the expression level of Spt5 
was improved by the bicistronic expression strategy, I had to cope with 
substoichiometric quantities upon assembly. In addition, the speculation of a 
prevailing propensity to improper folding is reflected by the aberrant retention 
volume of Spt5. Moreover, evidence that aggregation occurs and possibly impairs 
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complex formation, comes from the shoulder in the elution profile. The genuine 
RNAP II peak of Superose6 is of Gaussian shape. Coincident with performing the 
assembly, the stability of RNAP II alters.  
5.2 Rpb7/Spt4 fusion protein 
Tethering the components of multiprotein complexes creates new possibilities for 
exploring the nature and detail of protein–protein interactions, and can also be 
used to create novel functional combinations. The original impetus for tethering 
full-length Spt4 to the C-terminus of Rpb7 stems from the finding that in Sulfolobus 
acidocaldarius the DNA-directed RNA polymerase subunit E, which comprises the 
eukaryotic Rpb7-like N-terminal domain, is linked to another polypeptide E", which 
is on the other hand homologous to eukaryotic Spt4 (Ponting, 2002).  
Here we envisaged that the conjunction of yeast Rpb7 to Spt4 alone, or in 
combination with a Spt5 variant, may recruit the Spt4-Spt5 complex to the RNAP II 
surface. The physical attachment of Spt4 to RNAP II should counteract potential 
transient interactions occurring during crystal growth. In addition, the creation of a 
fusion protein by sequence-informed tethering of Spt4 to Rbp7 was expected to 
facilitate the identification of Spt4-Spt5 on the RNAP II surface by defining the 
amino acid residues either important for interactions between DSIF or necessary for 
establishing the 'checkpoint complex'. Furthermore, the first attempt to create a 
complex consisting of RNAP II and Spt4-Spt5 indicated that the conditions of this 
experiment were still suboptimal. Therefore a new proceeding for creating a 
composite of both the RNAP II and an elongation factor was chosen.  
5.2.1 Purification of an artificial Rpb7/Spt4 and Rpb4 complex 
In order to make the fusion protein amenable to random interactions with RNAP II 
surface, a flexible, glycine rich linker was introduced between the two distinct 
proteins. According to the cloning procedure a linker containing 15 glycine residues 
was intended. But additionally, a linker comprising only 13 glycines was obtained 
and as no frameshift was introduced into the gene sequence this variant was also 
expressed and purified. The exact protocols for purification of the different linker 
variants of the Rpb7/Spt4 and Rpb4 complex are given in chapter 10.3.2. As 
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examined by Coomassie staining, the complex containing the 13 glycine linker 
showed great promise for the rate of yield and was therefore chosen for all ongoing 
experiments. After releasing the complex from the Ni-NTA affinity column, 
numerous different buffer conditions were tested for the following purification steps 
to achieve homogenous material for crystallization. The final protocol consists of a 
MonoS- and Superose6 column (Figure 9).  
 
Figure 9. Purification procedure of an artificial Rpb7/Spt4 and Rpb4 complex. The 
chromatograms depict the typical purification procedure of the protein pair. The MonoS profile highlights 
the high DNA content in the sample. The polishing step comprises a gel filtration. The inset shows 3 μg 
of concentrated and highly homogenous Rpb7/Spt4-Rpb4 and the expected marker band at 31 kDa.  
5.2.2 Assembly of complex12 
Another possible benefit of the fusion protein lies in its potential for structure 
determination by molecular replacement. As the 12-subunit comprising RNAP II was 
already known (Armache et al., 2003) it was assumed that the attachment of 122 
additional amino acids would not influence the overall structure but rather provide a 
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template where Spt5 might join RNAP II. For this reason complex12 was assembled 
and the stability monitored by Superose6 gel filtration. The binding was 
demonstrated by a peak shift of the Rpb7/Spt4-Rpb4 proteins and a Coomassie-
stained SDS-polyacrylamid gel (Figure 10). At the first sight, the behaviour of this 
complex12 was comparable to the genuine Rpb4-Rpb7 subunits of RNAP II 
(Armache et al., 2003). 
 
Figure 10. Assembly of fusion protein Rpb7/Spt4 and Rpb4 with core RNAP II. The 
chromatogram depicts a typical gel filtration profile. Like in the case of genuine RNAP II, the elution 
volume of approximately 12 ml corresponds to the reconstituted enzyme, and the excess of recombinant 
proteins elutes at approximately 16 ml. The Coomassie stained SDS-PAGE demonstrates the purity of 
the modified RNAP II. Both the chromatogram and the SDS-PAGE analysis are derived from two different 
assembly reactions. Nevertheless, they are typical representatives of this highly reproducible 
experiment.  
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5.2.3 Crystallization of complex12 
Preparations of reconstituted RNAP II were homogeneous according to size 
exclusion chromatography. The collected peak fractions were concentrated and the 
complex subjected to different crystallization conditions (Table 1). These were 
successfully used in former times for crystallizing the genuine RNAP II by the 
hanging drop vapor diffusion method. A first indication for the influence of the 
hybrid protein onto the crystal formation was given by the new morphology of the 
crystals grown in (NH4)NaTartrat/Hepes conditions (Figure 11) and the downstream 
freezing procedure. Resulting from the known, high solvent content of RNAP II 
crystals, the established stepwise freezing protocol was applied (see PhD-thesis 
Armache, 2005). According to this, glycerol was added up to 22 % to the mother 
solution and the crystals were allowed to cool down slowly over night to 8 °C before 
flash frozen in liquid nitrogen. In my case the crystals began to dissolve when event 
treated with low concentrations of glycerol and this morphology was not 
reproducible in this condition. In addition, crystals were obtained with other 
solutions (Table 1). Thus, synchrotron analysis of the crystals only revealed the 
known RNAP II structure. Despite the size of the crystals of about 0.17 x 0.17 x 0.1 
mm, diffraction extended only to 4.0 Å in favourable cases. Albeit I could obtain 
crystals with a hexagonal morphology (0.17 x 0.17 x 0.07 mm) in the 
NH4NaTartrate/PEG/KSCN condition, they did not crystallize in another point group 
than the genuine RNAP II. 
  
(NH4)NaTartrate NH4NaTartrate/ 
PEG/KSCN 
Na3Citrate/PEG 
Figure 11. Single crystals of complex12. These typical representatives were obtained by the hanging 
drop vapor diffusion method. The well-established conditions are summarized in Table 1.  
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5.3 Rpb7/Spt4 and Rpb4 complex plus Spt5 variants 
Two kinds of elaboration determined the amino acids which are necessary for Spt5 
to interact with RNAP II. One study showed that the part of human Spt5 spanning 
amino acid residues 313 to 755 is capable to bind to RNAP II (Ivanov et al., 2000). 
An earlier study even cut the binding region down to amino acid residues 313 to 
420, a region which lays in between KOW domain 1 and KOW domain 2 (Yamaguchi 
et al., 1999). In order to combine the structural insights gained from the Aquifex 
aelicus crystal structure (Steiner et al., 2002) and expression studies with single 
Spt5 variants, new Spt4-Spt5 protein complexes were designed.  
5.3.1 Purification of Rpb7/Spt4 and Rpb4 complex plus Spt5 variant1 
On the basis of these results, and guided by sequence conservation and secondary 
structure analysis I designed three N- and C-terminal deletion constructs. The 
created Spt5 variants feature the region which is in accordance with the NGN-
domain and additionally either cover three or five KOW domains. The shortest 
variant contains three and the longest all five domains and additional residues with 
apparent low sequence homology. Already the fist purification step via the C-
terminal His6-tag revealed that the fusion protein complex (Rpb7/Spt4 and Rpb4) 
coexpressed with Spt5 variant1 (amino acid 283 – 620) was to a considerable 
degree more encouraging than the other variants (Figure 12). The C-terminal 
extended Spt5 variants seemed to be either impaired in expression (variant2; 
amino acid 283 – 849) or prone to degradation (variant3; amino acid 283 – 874).  
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Figure 12. Coexpression of the fusion protein complex with different Spt5 variants. The 
Coomassie stained SDS-acrylamid gel displays the 200 mM Ni-NTA elution profiles of Spt5 variant1 to 
variant3, which were coexpressed with the fusion protein complex. In addition, the domain architecture 
of the variants is shown, respectively.  
Extensive buffer screening was accomplished to maintain stoichiometry of this 
artificial complex. The purification protocol involved a MonoQ column, followed by a 
Superose6 column. This element was introduced as preliminary experiments with 
PEI (polyethylenimine) showed that DNA sticks to the desired protein and triggers 
precipitation (data not shown). In the first step the complex retained on the column 
and after elution two subsequent peaks were the outcome. At best, the peak 
fraction of the anion exchange column was considered which contained all three 
components in equal amounts (Figure 13). Already at this stage the purity of the 
protein sample was high. The latter step was the most crucial as the previously 
achieved stoichiometry was reversed by diverse buffer conditions. The Spt5 
variant1 showed the propensity to either interact with the column material or to 
precipitate in improper buffer conditions (data not shown). Therefore I abandoned 
the last polishing step and continued the experiments with concentrated MonoQ 
samples, keeping in mind that the salt concentration was approximately 450 mM. 
Nevertheless, aliquots of ammonium sulphate pellets containing 510 μg of protein 
could be flash frozen in liquid nitrogen and stored at -80 °C for later use. One liter 
of a standard expression culture yielded a purified, recombinant protein sample of 
7.5 mg/ml.  
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Figure 13. Purification of fusion protein complex plus variant1. The Coomassie SDS-PAGE analysis 
depicts a typical MonoQ elution of two successive peaks and demonstrates the purity/stoichiometry of 
the sample. The additional subunits are colored according to Figure 12 and chapter 10.3.1. 
5.3.2 Assembly of complex13 
The competence of Rpb7/Spt4 and Rpb4 plus Spt5 variant1 for complex formation 
with the core RNAP II was examined by a MembraSpin centrifugal concentrator. It 
is a common strategy to perform a binding assay by means of a concentrator 
instead of using a gel filtration column (personal communication I. Artsimovitch). 
On this account, the 100 kDa cut off was chosen to establish a stoichiometry 
complex and concomitantly get rid of protein excess. The components of the 
assembly were provided in their optimal buffer conditions and subsequently 
transferred into the crystallization buffer.  
Essentially, the linkage of Spt4 to Rpb7 aimed at increasing the effective local 
concentration of Spt5 on the RNAP II surface. Moreover, by providing a variant 
containing a segment involved in the Spt5 – RNAP II interaction the establishment 
of the 'elongation checkpoint complex' should be tackled a lot easier. Both 
assembly sample and flow through were monitored by SDS-PAGE (data not shown). 
The molecular weight of Rpb3 (45 kDa) is similar to that of Spt5 variant1 (39.7 
kDa) and both proteins run at the height near the 45 kDa marker band (Figure 14).  
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Figure 14. Assembly of RNAP II with Rpb7/Spt4 and Rpb4 plus Spt5 variant1. The Coomassie 
stained SDS-polyacrylamid gel displays the components and the quality of this artificial multiprotein 
complex. The constituents of the core RNAP II are shown in black. The additional subunits are colored 
according to Figure 12 and chapter 10.3.1. 
5.3.3 Crystallization of complex13 
The concentrated sample was used to obtain crystals by the hanging drop vapor 
diffusion method. Within days three dimensional crystals grew mainly in two 
conditions [Figure 15; (NH4NaTartrat/PEG/KSCN and NH4NaTartrat/Hepes)]. They 
were subjected to synchrotron radiation and diffracted until 4.5 Å.  
  
NH4NaTartrate/PEG/KSCN 
Figure 15. Single crystals of complex13. These typical representatives were preferentially obtained in 
the NH4NaTartrat/PEG/KSCN condition (Table 1).  
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5.3.4 Assembly of 'elongation checkpoint complex' 
Much of the processing of eukaryotic pre-mRNA into mature mRNA occurs 
cotranscriptionally and the recruitment of the capping machinery to the 
transcription complex marks the beginning of this multi step procedure (reviewed 
by Shatkin and Manley, 2000). All RNAP II transcripts are marked at their 5' ends 
by the addition of a methylated guanosine cap, when nascent RNA is about 20-25 
bases long. In this process Spt4-Spt5 plays a pivotal role. On the one hand, the 
manner of intimate recognition of this transcript by Spt4-Spt5 is still elusive, 
although the structural similarity between the NGN-domain and the RNP 
(Ribonucleoprotein) motif led to the speculation of a tuneable RNA binding site 
(Steiner et al., 2002). On the other hand there are compelling evidences that this 
bipartite elongation factor brings RNAP II to a halt at promoter proximal sites, 
thereby ensuring a time window for successful capping (reviewed by Orphanides 
and Reinberg, 2002). Consistent with the idea that Spt5 latches onto RNAP II in the 
presence of RNA, I constructed a DNA/RNA hybrid based on the solved structure of 
the nucleic acids in the elongation complex (Kettenberger et al., 2004). 
Additionally, a 22 nucleotide long overhang of the RNA was considered (Figure 16). 
Concomitantly, the 12-subunit containing RNAP II was assembled together with the 
Spt5 variant1 (chapter 10.4.4). This should constitute a situation whereby all 
participants of the proposed 'elongation checkpoint model' are on hand (Figure 17).  
 5' - GACCAGAAUAUAUAUGCAUAAA  
RNA                        GACCAGGC - 3' 
TEMPLATE 3' -        CCGTCATGATCATTACTGGTCCGCATTCATGAACTCGAACC - 5' 
NONTEMPLATE 5' -      CCGGCAGTACTAGTAAACTAGTATTGAAAGTACTTGAGCTT - 3' 
Figure 16. RNA/DNA hybrid. For the reconstitution of an 'elongation checkpoint complex' a 41-mer 
DNA duplex with an 11 nucleotide mismatched bubble region (blue), and an RNA 30-mer with eight 3'-
terminal nucleotides complementary to the DNA template strand in the bubble, was used.  
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Figure 17. Assembly of 'elongation checkpoint complex'. The Coomassie stained SDS-acrylamid gel 
displays the quality of the artificial 'elongation checkpoint complex'. Subunits of the core RNAP II are 
shown in black and additional subunits are colored according to Figure 12 and chapter 10.3.1. The two 
bands found around 66 kDa are impurities.  
5.3.5 Crystallization of 'elongation checkpoint complex' 
After assembly, the reconstituted RNAP II/Spt5 variant1 and nucleic acid complex 
was subjected to the usual RNAP II screen (Table 1). Extra DNA/RNA hybrid in the 
last cryo-solution should increase the occupancy in the crystals. Crystals grew to an 
ideal size of about 0.3 x 0.15 x 0.1 mm within 1 – 2 weeks at 20 °C. Figure 18 
shows typical representatives of crystals obtained under NH4NaTartrat/PEG/KSCN 
conditions described in Table 1. In addition, some set-ups were covered with 200 μl 
of Al's oil (paraffin oil : silicon oil / 1 : 1; Hampton Research). In my case, this 
treatment did not improve the average crystal size.  
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with oil layer NH4NaTartrat/PEG 
/KSCN 
 
Figure 18. Single crystals of 'elongation checkpoint complex'. Crystals were obtained in condition 
NH4NaTartrat/PEG/KSCN (Table 1). This condition tends to phase separation and crystals have to be 
harvested quickly.  
5.4 Structural analysis and data survey 
The endogenous core RNAP II of yeast was prepared as described elsewhere (PhD 
thesis Armache, 2005). Crystals were harvested and treated with the appropriate 
cryo-protectant. The protocol comprises six distinct steps at which the amount of 
glycerin in the mother solution is increased. Subsequently the crystals were 
annealed from 20 to 8 °C and frozen in liquid nitrogen. Diffraction data from single 
cryo-cooled crystals were collected at beamline X06SA at the Swiss Light 
Source/Switzerland. An overview of the data collection statistics is given in Table 2. 
The particular name of the crystal was derived from its composition. Based on the 
core RNAP II extra subunits were appended. Addition of Rpb7/Spt4-Rpb4 generated 
complex12 (chapter 5.2.3), whereas supplementary added Rpb7/Spt4-Rpb4 and 
Spt5 variant1 created complex13 (chapter 5.3.3). The complex termed 'elongation 
checkpoint complex' refers to 12-subunit RNAP II (with artificial Rpb7/Spt4), 
Spt5variant1 and DNA/RNA hybrid (5.3.5).  
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Table 2: Statistics of representative crystals 
Crystal name complex121 complex12 complex13 
'elongation 
checkpoint 
complex' 
Space goup C2221 C2221 C2221 C2221 
Unit cell axes (Å) 
222.1 
393.4 
281.4 
221.3 
393.8 
280.9 
224.745 
399.141 
290.7 
221.4 
393.8 
282.5 
Wavelength (Å) 0.920039 0.920039 0.97937 0.91929 
Resolution range 
(Å) 
50.0 – 4.0 
(4.14 – 4.0)2 
50.0 – 4.31 
(4.46 – 4.31) 
50.0 – 4.5 
(4.66 – 4.50) 
50 – 4.2 
(4.35 – 4.2) 
Unique reflections 101254 9995 
150571 
15119 
68639 
5641 
88470 
8280 
Completeness (%) 99.9 (99.8) 94.6 (95.1) 90.9 (75.3) 98.5 (92.9) 
Redundancy 4.2 (4.1) 3.8 (3.8) 4.4 (2.6) 5.3 (3.9) 
Mosaicity (°) 0.48 0.57 0.70 0.60 
Rsym (%) 8.5 (29.7) 9.8 (30.6) 7.4 (13.6) 16.6 (36.2) 
I/σ(I) 16.0 13.2 10.2 9.0 
Rcryst after rigid 
body refinement 30.2 31.8 38.9 33.8 
1 The corresponding electron density will be depicted in Figure 20. 
2 Values in parentheses correspond to the highest resolution shell. 
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5.4.1 The 12-subunit RNAP II model 
As followed from the crystallographic analysis with DENZO, the distinct complexes 
crystallized in the orthorhombic space group C2221 with quite similar unit cell 
dimensions. Data reduction was accomplished with DENZO and SCALEPACK. For 
molecular replacement the program PHASER was chosen. Based on the 1Y1W PDB 
entry the 12-subunit RNAP II model is shown in Figure 19. The clamp and bridge 
helix are kept in green. Rpb4 is presented in red and Rpb7 in light blue. In order to 
highlight the C-terminus of Rbp7 it is depicted in dark blue. The remainder of the 
enzyme is colored in light pink. The electron density is shown in white, respectively. 
The model is shown in a back view and tilted downward to emphasize Rpb4-Rpb7. 
 
Figure 19. 12-subunit RNAP II model. The model is derived from the 1Y1W PDB entry. 
5.4.2 Electron density map of complex12 
At best the crystals of RNAP II comprising the artificial Rpb7-Spt4 subunit were 
diffracting until 4.0 Å. In Figure 20 A the superposition of the electron density and 
the clamp/bridge helix are shown to get an idea of the quality of the calculated 
2fofc-map at a contour level of 1.7σ. In Figure 20 B the electron density is 
highlighted which represents Rpb7 and Rpb4 and in which Rpb4 nicely fits. In the 
case of Rpb7 the situation is different. The N-terminal and middle part of the 
protein is well defined but for the corresponding extreme C-terminus I could not 
find an interpretable electron density. The protein segment from leucine 168 to 
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isoleucine 171 is lacking. But actually this is the most interesting part. The C-
terminal region and the glycine linker should make a contribution to position Spt4 
in proximity to RNAP II. Unfortunately, no subtle hint of the location of Spt4 could 
be achieved with this experimental approach. The linker probably allowed Spt4 to 
be flexible attached to the RNAP II surface and did not enforce a distinct position. 
The lack of density may suggest the possibility that Spt4 populates alternative 
conformations. So far, Spt5 has been implicated to recruit the bipartite elongation 
factor to the transcription machinery. The assembly of RNAP II comprising an 
artificial subunit could not enforce the formation of a physical interaction between 
Spt4 and the enzyme additive to the glycine linker. Under these conditions, the 
experiment suggests that Spt5 is the prerequisite for the aspired multiprotein 
complex. 
A)  complex12 
electron density of the clamp/bridge helix 
 B)  complex12 
electron density of Rpb7-Rpb4 
 
 
 
Figure 20. Electron density map of complex12. The contour level is 1.7σ. The remaining electron 
density map belongs to the symmetry mate. 
5.4.3 Electron density map of complex13 
The crystals comprising core RNAP II, heterologously expressed artificial 
Rpb7/Spt4-Rpb4 and Spt5 variant1 diffracted until 4.5 Å. In Figure 21 A, the 
electron density map (contour level 1.7σ of the 2fofc map) covered the residues of 
the clamp and the bridge helix. Figure 21 B is highlighting the superposition with 
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Rpb7-Rpb4 at a contour level of 1.7σ. The underlying experimental setup should be 
a watershed and Spt4 was expected to assist both the recruitment of Spt5 variant1 
and the positioning on the RNAP II surface. Strikingly, despite of the crystal size 
and careful data analysis, it was not possible to localize Spt4-Spt5 on the RNAP II 
surface by assigning any of the additional density (albeit weak) to this elongation 
factor. The density of the protein segment of Rpb4 which emanates from the 
RNAP II surface seems to be slightly shifted. Apparently, the helices three, five and 
six are identifiable but do not match the predicted and expected position. The early 
idea that tethering of Spt4 with Rpb7 should create a formidable precursor for 
macromolecular complex formation did not prove true. But rather the converse was 
observed. The addition of Spt4-Spt5 to a previously well behaving system seems to 
influence an established tertiary structure. These findings argue for an alternative 
assembly of Spt4 and Spt5 variant1 with RNAP II. The brief residency of Spt5 
observed here is difficult to reconcile with the opinion that DSIF is a powerful 
transcription elongation factor and tends to bind as strongly to RNAP II as TFIIS.  
A)  complex13 
electron density of the clamp/bridge helix 
 B)  complex13 
electron density of Rpb7-Rpb4 
 
 
 
Figure 21. Electron density map of complex13. The contour level of both 2fofc maps is 1.7σ.
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5.4.4 Electron density map of 'elongation checkpoint complex' 
Bringing together different components in a reaction tube and skipping of further 
polishing but lossy steps should raise the local concentration of the interaction 
partners and increase the probability of complex formation. The additives were 
expected to bind to the 'rigid body' of the enzyme. At best the crystals of RNAP II 
comprising the artificial Rpb7-Spt4 subunit and a DNA/RNA hybrid were diffracting 
until 4.2 Å. But nevertheless, it does not engender a situation whereby one can 
reasonably posit a role or location for Spt4-Spt5 in the assumed macromolecular 
assembly. Rpb4 and Rpb7 fit well into the 2fofc map (contour level 1.7σ) but do not 
reveal the destiny of the glycine linker and Spt4 as the display detail in Figure 22 A 
shows. Figure 22 B depicts the model in a front view. In Figure 22 C and 22 D the 
wall (magenta) and the hybrid binding site (cyan) of Rpb2 are highlighted, 
respectively. In figure 22 D the perspective is chosen to have a direct view onto the 
hybrid binding site by omitting interfering protein segments. 
Concerning the wall and the hybrid binding site, both regions are defined in the 
electron density map but confusingly the contribution of the hybrid is missing. It 
was expected that during the assembly procedure the 12-subunit RNAP II will 
locate the DNA/RNA hybrid in position allowing the process to be recapitulated. 
After all, the assembly was performed in the same order as it was done for the 
complete RNAP II elongation complex structure (Kettenberger et al., 2004). Over 
and above, evidence that addition of DNA/RNA can improve the affinity of Spt4-
Spt5 variant1 for the enzyme could not be perceived. Seemingly, the nucleic acids 
are not present in the complex and the additional proteins can not be ascertained. 
The generation of a higher complex containing RNAP II and the heterodimeric 
protein pair Spt4-Spt5 seems to be hampered. Except for the transcription 
elongation factor TFIIS, which easily bound to the enzyme, a major lacuna in the 
search for RNAP II-transcription complexes remains as the full biological 
significance of the RNAP II structure lies in the implications for the higher 
complexes formed with different transcription factors. Consequently, this 
experimental approach to create an 'elongation checkpoint' by adding recombinant 
components to endogenous core RNAP II does not provide insights into the 
interacting components and the atomic details of this biochemically well-studied 
association.  
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A)  'elongation checkpoint 
 complex' 
electron density of Rpb7-Rpb4 
 B)  12-subunit model 
 
 
 
 
C)  wall 
electron density of the wall and the clamp 
 D)  hybrid 
electron density of hybrid binding region 
 
 
 
Figure 22. Electron density map of the bubble-complex. The contour level of the 2fofc maps is 1.7σ. 
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5.5 Data interpretation 
Although the here presented studies advocate a physical interaction between 
RNAP II and Spt4-Spt5, the atomic model of this complex as positive proof is still 
missing. Assembling the components together like pieces of a puzzle does not meet 
demands of an 'elongation checkpoint complex', allowing the process to be 
recapitulated using purified constituent parts. But how can such complex formation 
be accomplished and structurally exploited? 
The design of the investigated Spt5 variants was based upon the domain 
organization of this elongation factor, focussing on the possible molding of the 
KOW-domains in the presence of RNAP II as its binding partner. I assumed that the 
proteins will either interact by domain-domain or protein-motif contacts. Separately 
purified heterologous components assembled efficiently with endogenous core 
RNAP II but did not form an unequivocally and stable unit which could be captured 
by protein crystallography. On the first sight, I could conclude from these 
crystallographic analyses that my recombinant Spt4-Spt5 proteins lack properties of 
their wild type counterparts, thereby anticipating the complex to be reconstructed 
in vitro. Concerning the fusion protein approach, either an apparently disordered 
nature of Spt4 hampers a specific interaction with the RNAP II surface or Spt4 lacks 
an intrinsic binding capability. What’s more, it does not confer interaction specificity 
for the enzyme upon the Spt5 variant1 which could be trapped in a rigid crystal 
lattice. A phenomenon I could observe was that the contribution of approximately 
100 amino acid residues at the N-terminus of Spt5 highly influenced the nature of 
the protein sample. The segment from amino acid residue 283 to 379 always 
caused problems. I run the gamut from impaired expression levels to exceptional 
behaviour on a size exclusion column. As soon as I changed the segment of Spt5 
the fidelity changed. This is rather astonishing as the mentioned region has a 
predicted function (part of the Spt4 binding region) and the Aquifex aelicus crystal 
structure (Steiner et al., 2002) bodes well for revealing the structure of this 
evolutionary conserved NGN-domain. It may be such that the plasticity of this 
domain makes Spt5 amenable for specific conformations which I could not trap with 
the rational design of my Spt5 variants.  
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Collectively, the model of a Spt4-Spt5/RNAP II complex awaits further proof and I 
reason that potential antagonistic processes underlying my experimental-setup may 
also result from either absent posttranslational modifications or an obstructed 
'induced fit mechanism'. Spt5 has been demonstrated as a direct methylation target 
(Kwak et al., 2003). PRMT5 and PRMT1 likely play an important role in altering the 
protein-protein interaction of DSIF and RNAP II. Methylation of Spt5 is speculated 
to diminish its association propensity with RNAP II. Regarding my experiments, the 
Spt5 variant1 is lacking this domain, whereas Spt5 variant3 comprises this segment 
and both variants bind to RNAP II. Actually, there are no counterparts in yeast for 
the predicted methylation sites in human Spt5. Guided by the GRG sequence motif 
stimulating methylation by PRMT1, there could be a single, adequate site lying in 
between the predicted ones. Nevertheless, it has to be considered that insensible to 
the existence of this region in the designed proteins, Escherichia coli is not capable 
of accomplishing posttranslational modifications. Notwithstanding these facts, I 
speculate that the acidic N-terminus and/or the repetitive C-terminus could 
orchestrate the binding onto RNAP II in a yet not established manner. It has been 
shown that the KOW-domains potentiate the binding but by virtue of 
crystallography I neither could confirm this simple rule nor present a mechanism 
based on the domain organization. The C-terminus of Spt5 is termed 'mini-CTD' 
which is phosphorylated in the process of transcription elongation (Yamada et al., 
2003). Additional posttranslational modifications on both termini or on a distinct 
terminus could influence the direct and well-defined establishment of the 
'elongation checkpoint complex'. Another possibility could be that the generated 
Spt4-Spt5 conjugates are missing a not previously detected but important protein-
protein binding region that undergoes a disorder-to-order transition as Spt5 binds 
to RNAP II. It is becoming increasingly clear that many functionally important 
protein segments occur outside of globular domains (Linding et al., 2003) and that 
a couple of interactions involve unstructured parts of a protein that becomes 
ordered only on binding to its partner (reviewed by Aloy and Russel, 2006; 
Radhakrishnan et al., 1997). In my case, upon complex formation either the 
predicted unstructured N-terminus or the C-terminus could become ordered and 
extend the interaction interface. As mentioned above, the C-terminus of Spt5 is 
alike the CTD of RNAP II. Latest results propose an evolutionary conserved 
reccuring pentapeptide motif in the CTR (C-terminal region) of hSpt5. In addition, 
C H A P T E R  I I :  R E S U L T S  A N D  D I S C U S S I O N  
51 
this consensus sequence G-S-R/Q-T-P is the target site of P-TEFb, which also 
phosphorylates the CTD, thereby controlling the elongation phase of transcription 
(Yamada et al., 2006; reviewed by Peterlin and Price, 2006). Nevertheless 
significant differences exist. For instance, the CTR repeats are not contiguous and 
are not located at the extreme C-terminus. Strikingly, in the case of Saccharomyces 
cerevisiae, it was not possible to pinpoint a consensus motif. Regarding this thesis, 
the difficult generation and the varying life span of the Spt4-Spt5/RNAP II complex 
could also be a reflection of the distinctive feature of the C-terminus of budding 
yeast.  
Last but not least, the role of Spt4 in the heterodimeric transcription elongation 
factor still remains elusive. Spt4 has been exclusively assigned to exert a positive 
role in transcription elongation. It may regulate the switch to processive 
transcription as it overcomes the Isw1p-dependent pausing of RNAP II at the onset 
of elongation (Morillon et al., 2003). In addition, spt4Δ cells are impaired in 
transcription of lacZ and other long and GC-rich DNA sequences driven from the 
GAL1 promoter (Rondon et al., 2003). The mechanism how Spt4 interacts with Spt5 
has not yet been investigated. This would allow a functional dissection of their 
complementary but perhaps also different impact on the process of transient 
pausing of RNAP II. This aspect merits further examination. Latest results suggest 
that the phosphorylation pattern of Spt5 accounts for its dual function (Yamada et 
al., 2006). DSIF is clearly capable of both repressing and activating transcription 
under different conditions (Yamada et al., 2006 and reference therein). According 
to my experiments, I can deduce that Spt4 has a profound effect on the stability of 
Spt5. I could hardly get any material from a two liter culture when Spt5 variant1 
was expressed in isolation. Even in the case where Spt4 was fused to Rpb7, the 
amount of coexpressed Spt5 variant1 proved satisfactory and the quality of the 
sample was suitable for crystallization trials. The basis for specific 
heterodimerization is unknown, and must be investigated. 
C H A P T E R  I I :  R E S U L T S  A N D  D I S C U S S I O N  
52 
6 STRUCTURE AND CTD-BINDING OF THE SET2 SRI DOMAIN 
THAT COUPLES HISTONE H3 LYSINE 36 METHYLATION TO 
TRANSCRIPTION 
The appreciation that maturation of nascent mRNA occurs by interdependent and 
cotranscriptional processes that are physically and functionally connected by the 
CTD has changed the view of gene transcription. Currently, each stage is 
considered as a subdivision of a continuous process (reviewed by Orphanides and 
Reinberg, 2002). In addition, the role of chromatin has been adjusted from a 
packaging device to a highly dynamic unit whose modifications influence gene 
transcription (reviewed by Mellor, 2006). Until recently, both activities were 
regarded on their part as autonomous. This narrow perspective is changing as 
accumulating evidence suggests that histone methylation plays an important role in 
the process of transcription elongation. While transcribing coding regions, the CTD 
of RNAP II mediates methylation of H3K36 by Set2. This distinctive histone lysine 
methyltransferase is associated with RNAP II in a manner that is dependent both on 
the CTD and the Ctk1/Bur1 kinases that phosphorylate the CTD on serine 2. The 
precise region in Set2 which is required for crosstalk with RNAP II was determined 
lately and termed SRI-domain (Kizer et al., 2005). These findings were so 
innovative to catch my attention and structural biology methods like NMR 
spectroscopy and X-ray crystallography are prolific techniques to illuminate the 
relationship between Set2 and RNAP II.  
6.1 Domain mapping and crystallization of SRI domain variants 
I have used a combination of available bioinformatic methods for predicting protein 
secondary structure and published interaction studies (Kizer et al., 2005) to design 
several SRI domain variants. First crystallization attempts with different variants 
comprising additional segments N- and C-terminal of this domain failed. It was not 
possible to narrow down the crystallizable protein segment experimentally by 
repeating experiments with smaller constructs. Extensive screening with various 
protein samples at discrete concentrations or usage of diverse commercial screens 
did not lead to crystals. Furthermore, a change in temperature to influence the 
crystallization process was not fruitful.  
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In a new approach as it is depicted in Figure 23, I did not confine the SRI domain to 
the proposed region but rather deleted several additional amino acids to increase 
the likelihood of crystal growth. An expression plasmid based on pET24d and 
containing an N-terminal hexahistidine tag was used to produce several N- and C-
terminal truncations of the SRI domain.  
 
Figure 23. Set2 SRI sequence. The investigated SRI domain comprises amino acids 619 to 718 in 
yeast. The helical regions predicted by PredictProtein (http://cubic/bioc/columbia/edu/ 
predictprotein.hmtl), a secondary structure prediction surfer, are marked in green. In addition, primer start 
sites are indicated. 
I was expecting that the newly generated SRI variants make it possible to harness 
the technology of X-ray crystallography to look for the atomic details of the SRI 
domain alone or in conjunction with a CTD peptide (Figure 24). For this reason two 
synthetic equivalents were ordered at the companies Jerini (http://www.jerini.com/) and 
Anaspec (http://www.anaspec.com/). As there was no indication neither for the 
crystallization condition nor for the sample concentration, I did several varying set-
ups as summarized in Table 3. The molar ratio SRI domain : peptide was 1 : 1.25. 
Unfortunately, cocrystallization of the putative interacting partners did not yield 
crystals.  
 
Figure 24. The Sequence of CTD-peptides. The two CTD-peptides are depicted which were used for 
the crystallization set-ups.  
Concomitantly accomplished crystallization set-ups of the SRI domain alone gave 
crystals in two cases but only after 3 months (Figure 25). The aberrant crystallizing 
degradation products could not be identified. The variants comprising amino acids 
632 – 707 or 632 – 709 are further truncated at the N-terminus but in contrast did 
not crystallize. The applicability of this approach was limited as the very thin and 
tiny crystals could not be reproduced. Albeit the proteins were not crystallizing it 
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was obvious that they were pure and highly soluble. With this knowledge I pursued 
a new strategy to shed light into the structure of this extremely interesting domain. 
I decided to tackle the problem by NMR spectroscopy.  
Table 3: Crystallization setups with different SRI variants/peptides 
SRI variant [c] Crystallization screen peptide 
aa 624 – 705 n. d.   
aa 624 – 707 6 mg/ml 
6 mg/ml 
Classic HTS3 
Classic HTS3 
 
jPT 
aa 624 – 709 40.0 mg/ml 
18.5 mg/ml 
Natrix/ PEG-Ion/ MPD suite1 
Classic HTS3 
 
Anaspec 
aa 629 – 705 10.5 mg/ml Classic HTS Anaspec 
aa 629 – 707 31.0 mg/ml 
31.0 mg/ml 
16.3 mg/ml 
16.3 mg/ml 
Index1 
Classic2/ Cations2 
Classic2 
Classic HTS3 
 
 
Anaspec/ jPT 
Anaspec/ jPT 
aa 629 – 709 12.8 mg/ml Classic2 Anaspec 
aa 632 – 705 n. d.   
aa 632 – 707 13.3 mg/ml Classic2 Anaspec 
aa 632 – 709 11.5 mg/ml Classic2 Anaspec 
1 Hampton research (www.hamptonresearch.com/) 
2 Nextal (http://www.nextalbiotech.com/) 
3 Jena bioscience (http://www.jenabioscience.com/) 
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SRI variant aa 624 – 709 
CdSO4 HYDRATE 
SRI variant aa 629 – 707 
CdSO4 HYDRATE 
Figure 25. Preliminary crystals of two SRI domain variants. Crystals were obtained in conditions of 
the commercial screen Nextal2 Classic Suite #39 containing 0.05 mM CdSO4 hydrate/0.1 M Hepes pH 
7.5/0.5 M sodium acetate anhydrous.  
Before I could start to elucidate the structure by NMR spectroscopy I had to reclone 
my protein for two reasons. Firstly, a substantially feature of the SRI domain is its 
vast content of lysines, exactly 20 %. Therefore I had to reduce any additional 
positive charge by removing the hexahistidine tag. Secondly, for the expression of 
isotope labelled protein the amount of culture should not extend two litres. To fulfil 
both requirements I subcloned the coding sequence of the SRI domain into a 
modified pET9d vector, which was kindly provided by G. Stier from 
EMBL/Heidelberg. The containing z-tag was thought 'to boost' the expression and 
by means of the TEV-cleavage side I could remove the tag. This also gave me the 
opportunity to go back to the 'full length' SRI domain to delineate the whole protein 
segment promoting the interplay with RNAP II. 
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6.2 The Set2 SRI domain forms a conserved three-helix bundle  
The solution structure of the yeast Set2 SRI domain was determined by 
multidimensional NMR (Table 4). The structure revealed three α-helices arranged in 
a left-handed bundle (Figure 26 B). The N-terminal helix α1 is slightly kinked at 
residues F639 and V640, and the linker between helices α1 and α2 includes a short 
310-helical turn at residues S650-Q652. A hydrophobic core is formed by numerous 
residues located at the interface between the three helices, including four residues 
in the two regions linking the helices (Figure 26 C). Consistently, the heteronuclear 
{1H}-15N NOE measurements demonstrate that the polypeptide backbone in all 
three helices and the connecting linker regions is rigid (Figure 26 C). The 
hydrophobic core residues are generally conserved across species (Figure 26 C), 
demonstrating that our structure is a good model for SRI domains in Set2 of other 
species. 
C H A P T E R  I I :  R E S U L T S  A N D  D I S C U S S I O N  
57 
 
Figure 26. Structure and CTD binding of the yeast Set2 SRI domain.  
A) ensemble of final NMR structures. The three α-helices are shown in green, and a short 310-helix is 
shown in pink.  
B) ribbon diagram of the lowest energy structure in A.  
C) alignment of SRI domain sequences and NMR structure determination and CTD binding data. The 
secondary structure is shown above the sequence. Solvent-protected amide protons that show slow H/D 
exchange are indicated by filled circles. Secondary chemical shifts Δδ(Cα-Cβ) are indicated by black bars. 
Residues that experience large chemical shift perturbations upon addition of the CTD two-repeat 
phosphopeptide SPS-YpSPTpSPS-YpSPTpSPS (pS = phosphoserine) are indicated above the alignment 
with crosses and circled crosses for backbone and side chain amides, respectively. Yellow stars indicate 
residues Ala662 and Val666 that are implicated in binding of a CTD tyrosine side chain. Residues that 
are identical and conserved in fungal Set2 homologues are on red background and in red, respectively. 
Hydrophobic core residues are marked with a black square. 
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Table 4: NMR structural statistics for the yeast Set2 SRI domain 
 <SA>1 <SA>water-ref 
Number of NOE derived distance restraints   
All (unambiguous/ambiguous) 
Long range |i-j|> 4 (unambiguous/ambiguous) 
1958/198 
433/26 
 
R.m.s. deviation (Å) from experimental 
distance restraints2 
  
R.m.s.d. (NOEs) 
Hydrogen bonds (2*20) 
0.0147±0.0005 
0.026 ± 0.004 
0.025±0.006 
0.043 ± 0.006 
R.m.s. deviation (°) from experimental 
torsion restraints3 
  
R.m.s.d. (83 Φ/Ψ) 0.68 ± 0.07 0.88 ± 0.12 
Coordinate Precision (Å) residues 10-944   
   N, Cα, C'  
   All heavy atoms 
0.38 ± 0.06 
1.01 ± 0.05 
0.48 ± 0.08 
1.05 ± 0.06 
Structural quality5   
Bad contacts 1.8 ± 0.8 0.0 ± 0.0 
Ramachandran plot   
   % in most favored region 
   % in additionally allowed region 
90.2 ± 1.4 
9.4 ± 1.4 
93.6 ± 1.6 
6.3 ± 1.6 
1 <SA> is an ensemble of ten lowest-energy solution structures (out of 100 calculated) of the Set2 SRI 
domain before water-refinement. The CNS Erepel function was used to simulate van der Waals 
interactions with an energy constant of 25.0 kcal mol-1 Å-4 using “PROLSQ” van der Waals radii; r.m.s. 
deviations for bond lengths, bond angles and improper dihedral angles are 0.0020 ± 0.0001 Å, 0.382 ± 
0.008° and 0.31 ± 0.01°. 1 kcal = 4.18 kJ. 
2 Distance restraints were employed with a soft square-well potential using an energy constant of 50 
kcal mol-1Å2. For hydrogen bonds, distance restraints with bounds of 1.8-2.3 Å (H-O), and 2.8-3.3 Å (N-
O) were derived for slow exchanging amide protons. No distance restraints were violated by more than 
0.3 Å in the <SA> structures. 
3 Dihedral angle restraints derived from TALOS (Cornilescu et al., 1999) were applied to backbone 
angles using energy constants of 200 kcal mol-1 rad-2. No dihedral angle restraint was violated by more 
than 5°. 
4 Coordinate precision is given as the Cartesian coordinate r.m.s. deviation of the 10 lowest-energy 
structures in the NMR ensemble with respect to their mean structure. 
5 Structural quality of the NMR ensemble was analyzed using PROCHECK (Laskowski et al., 1996). 
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6.3 The SRI domain defines a novel CTD-binding fold  
Comparison with the five known structures of CTD-binding domains reveals that the 
SRI domain defines a novel CTD-binding fold. Other CTD-binding domains include 
FF domains, CTD-interacting domains (CIDs), WW domains, BRCT domains, and a 
domain in the Cgt1 subunit of the 5'-capping enzyme (reviewed by Meinhart et al., 
2005). Of these, FF and CID domains also form helical bundles (Allen et al., 2002; 
Meinhart and Cramer, 2004) but, in contrast to the SRI domain, the superhelical 
arrangement in these two domains is right-handed (Figure 27). Thus the six CTD-
binding domains that have been structurally characterized use different folds for 
specific CTD recognition. 
 
Figure 27. Comparison of the Set2 SRI domain with known helical CTD-binding folds. The 
structures are shown as ribbon models colored from blue to red from the N- to the C-terminus, 
respectively. Shown are from left to right: the Set2 SRI domain (this study), an FF domain, and the 
Pcf11 CID domain. For orientation of the structures, the N-terminal helices were superimposed. Note 
that the SRI domain shows a left-handed superhelical arrangement, whereas the two other domains 
adopt a right-handed arrangement. 
6.4 The SRI domain binds a two-repeat CTD phosphopeptide 
To characterize the CTD-binding determinants of the SRI domain, we performed 
NMR titration experiments with S2/S5-phosphorylated CTD peptides (Figure 28 C). 
A phosphopeptide consisting of a single CTD repeat (Figure 28 A, YpSPTpSPS, 
pS=phosphoserine) did not perturb chemical shifts in a 2D 1H, 15N HSQC spectrum, 
indicating that there is no significant binding (not shown). However, titration with a 
peptide that comprised two CTD repeats and three flanking N-terminal residues 
(SPS-YpSPTpSPS-YpSPTpSPS) resulted in many strong chemical shift perturbations 
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(Figure 26 C, Figure 28). From the titration data the dissociation constant is 
estimated to be in the low μM range, comparable to the reported approximate 
affinity of 6 μM for a CTD phosphopeptide comprising three repeats (Kizer et al., 
2005). 
 
Figure 28. NMR-monitored CTD binding of the Set2 SRI domain. 
A) Sequence of the two CTD peptides used for binding studies. The upper peptide did not bind the SRI 
domain, the lower peptide bound with an apparent dissociation constant in the low μM range. 
B) NMR titration experiment. Shown are 2D 1H, 15N-HSQC spectra before (black) and after (red) addition 
of a 1.25-molar excess of the two-repeat. 
6.5 Regions in the SRI domain that interact with the CTD 
Residues that show strong chemical shift perturbations of their backbone NH groups 
cluster in two regions on the SRI domain structure (Figure 29 A). The first region 
includes residues K634, F635 in α1, and A662, V666, K667, T670, T671, and E673 
in α2, whereas the second region includes residues F653, H655, E656 in the α1-α2 
linker, and residue I705 in α3 (Figure 26 C, Figure 29 A, Figure 28). With the 
exception of I705, the strongest perturbations upon peptide binding were observed 
in region 1 (F635, A662, V666, K667, and E673). In this region, the side chain NH2 
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groups of residues N631 and N633 also show significant chemical shift 
perturbations (Figure 28 B). Both regions are conserved among fungal Set2 
homologues (Figure 29 B), befitting the conserved function of the 
Schizosaccharomyces pombe and Neurospora crassa Set2 homologs (Morris et al., 
2005; Adhvaryu et al., 2005). The observation of two putative CTD-binding regions, 
and the finding that two CTD repeats are required for SRI domain binding, indicate 
that the phospho-CTD extends over a long distance along helices α1 and α2, and 
the connecting linker. 
 
Figure 29. Surface analysis of the Set2 SRI domain. Surface representation of the SRI domain color-
coded according to chemical shift perturbation of backbone NH and side chain NH2 groups upon binding 
of the CTD peptide (Figure 28 A), colored from red to blue for strong to weak perturbations, respectively 
(A); amino acid conservation among fungal homologues in the alignment of Figure 26 C (B); and 
electrostatic surface potential (blue and red for positive and negative charges, respectively) (C). 
6.6 CTD tyrosine side chains contribute to SRI domain binding 
The peptide titration experiments also revealed that the two-repeat CTD peptide 
(Figure 28 A) binds to the SRI domain via its tyrosine residues. Intermolecular 
NOEs between both CTD tyrosine side chains and the SRI domain were detected 
(not shown). Preliminary assignments indicate that one of the tyrosine side chains 
is in proximity of residues A662 and V666 in region 1 (Figure 26 C, Figure 29 B). 
These two residues are part of a hydrophobic patch between helices α1 and α2, and 
flanked by positively charged surfaces (Figure 29 C), as expected for interaction 
with the negatively charged phospho-CTD. Interestingly, the tyrosine-proximal 
residue A662 is identical in human Set2, as are F635, E656, and E673 in the 
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putative CTD-binding regions (Figure 26 C). In the three known CTD-protein 
complex structures, the Y1 side chain is also involved in hydrophobic contacts 
(Meinhart and Cramer, 2004; Fabrega et al., 2003; Verdecia et al., 2000), 
suggesting that Y1 binding is a general feature of CTD recognition. Previous studies 
revealed that the CTD can adopt different conformations (reviewed by Meinhart et 
al., 2005), and this structurally versatile nature of the CTD discourages any 
detailed model building. 
6.7 The SRI domain resembles a polymerase-interacting domain in 
bacterial sigma factors 
Comparison of our structure with known folds in the database DALI (Holm and 
Sander, 1995) strikingly shows that the SRI domain resembles a region in bacterial 
σ factors (Figure 30). The four highest hits were the sigma factors σ28 (PDB-code 
1rp3), σE (PDB-code 1or7), σR (PDB-code 1h3l), and σ70 (PDB-code 1sig), which 
show DALI scores of 5.6, 5.4, 5.1, and 4.9, respectively, and RMS deviations 
between 3.3 and 3.7 Å. The region in σ70 that is structurally related to the SRI 
domain is domain 2 (σ2), which interacts with the clamp region of the core RNAP II 
upon formation of the holoenzyme (Murakami et al., 2002). The σ2 domain is 
involved in binding the –10 element of promoter DNA and contributes to DNA 
melting during initiation (reviewed by Gross et al., 1998). In the eukaryotic 
initiation complex, promoter DNA around position -10 lies near the N-terminal 
domain of the initiation factor TFIIEα (Forget et al., 2004), which shows weak 
sequence homology (Okhuma et al., 1991) and structural similarity (Meinhart et al., 
2003) to the bacterial σ2 domain. We speculate that the eukaryotic TFIIEα N-
terminal domain, which may contact promoter DNA, and the Set2 SRI domain, 
which binds the negatively charged phospho-CTD, both evolved from the bacterial 
σ2 domain.  
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Figure 30. The Set2 SRI domain resembles a domain in bacterial σ factors. The domain in the 
σ factor that resembles the SRI fold is highlighted in green. The PDB codes of the structures are given in 
parentheses. 
6.8 Structural studies of CTD phosphopeptide and SRI domain-peptide 
complex 
6.8.1 Free CTD phosphopeptide 
The structural plasticity and divergent phosphorylation pattern of the CTD 
engenders a versatile landing pad for a consortium of different transcription factors, 
which recognize this site-specific modifications. In order to examine a putative 
secondary structure of the synthetic equivalent of the CTD used in this study, I 
performed several NMR experiments. These were in accordance to previous studies 
which led to the proposal that CTD-derived peptides do not form stable secondary 
structure elements (Noble et al., 2005; reviewed by Meinhart et al., 2005).  
A set of TOCSY and ROESY experiments recorded on SPS-YpSPTpSPS-YpSPTpSPS 
revealed several intraresidue correlations and a few crosspeaks consistent with Hα 
(serine)-Hδ (proline) correlations (Figure 31). On the first sight, the three 
Hα (serine)-Hδ (proline) correlations could point at the three Pro-Ser amino acid 
residue pairs in the sequence. Unfortunately, the Cα-H–NH region of the 
superimposed spectra did not clarify, if the observed NOEs are indeed sequential 
correlations or may arise from nonsequential residues due to secondary structure or 
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even belong to one of the Ser-Pro pairs in the peptide. Comparison of cis and trans 
Xxx-Pro protein fragments (where Xxx is any amino acid) shows that the distances 
between NHi, αHi, dCH2(i+1), and αH(i+1) are particularly strongly affected by the 
cis-trans isomerization. Thus, the cis form allows much closer contacts between αHi 
and αH(i+1) and between NHi and αH(i+1), whereas the trans form favors short 
distances between αHi and δCH2(i+1), and between NHi and δCH2(i+1) (Wüthrich, 
1986). Concerning the peptide sequence, I would assume to observe not only three 
but five of these highly specific interresidue NOEs, if the observed NOEs belong to 
Ser-Pro pairs. Albeit the Cα-H–NH region of the ROESY spectra provided additional 
evidence for two possible pSer-Tyr pairs (data not shown), a sequence specific 
assignment for this segment could, however, not be established. Conclusively, due 
to the repetitive character of the peptide it was not possible to infer a sequential 
connectivity. Hence, for this peptide, no sequence specific assignment could be 
made and no further structural studies were pursued.  
 
Figure 31. TOCSY and ROESY spectra of 'free' peptide. Both TOCSY spectra are superimposed and 
shown in red (mixing time 60 ms) and blue (mixing time 30 ms). The ROESY spectra is colored in green. 
One Hα (serine)-Hδ (proline) correlation is explicitly depicted. The spectrum was recorded on a 0.4 mM 
peptide sample in 100 % D2O. 
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6.8.2 Complex structure evaluation 
Distance restraints of the putative SRI domain-CTD phosphopeptide complex were 
derived from 2D NOESY or 13C-resolved 3D NOESY. Essentially, the procedure was 
the same as for the free SRI-domain. In contrast, the final ensemble of NMR 
structures was not refined, albeit NOE violations derived from ARIA were 
considered. The change in conformation of the protein with addition of peptide was 
weak. From the derived structure I can not deduce why two repeats of the CTD are 
a necessity for successful binding. The residues which are involved in binding 
cluster in two regions on the SRI domain structure (Figure 29 A) but the structure 
of the SRI domain in presence of the CTD phosphopeptide does not pinpoint how 
the small SRI domain, which comprises only 100 amino acid residues, binds this 
relatively large peptide (Figure 32).  
 
Figure 32. The preliminary SRI domain-peptide complex structure. The published free SRI domain 
is depicted in green and the preliminary complex structure is shown in pink. Ala662 is shown as stick. 
Almost concomitantly with the here presented work, the NMR solution structure of 
the human SRI domain was solved which displays 23/37 % identity/similarity to its 
yeast counterpart (Li et al., 2005). The SRI domain of HYPB (huntingtin yeast 
partner B) protein comprises the amino acid residues 1956 to 2056 of the C-
terminus and also adopts a left-turned three-helix bundle. After investigating the 
fact that a CTD peptide containing four contiguous Ser-2/Ser-5 phosphates is 
sufficient for maximal binding, mutagenesis studies were performed. By mapping 
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NMR perturbations, the binding site of the peptide was roughly assessed and the 
nearby side chains actually involved in the interaction should be defined more 
precisely. The outcome was a model which states that the positively charged 
residues from helix 2 (His62, R58, K54) contribute to the interface by providing 
docking sites for the negatively charged phosphoepitopes of Ser5 or Ser2. The 
principle of electrostatic anchors resembles therein the interface of the Cgt1-CTD 
peptide complex (Fabrega et al., 2003). It is speculated, that the spacing of the 
phosphoserines determines the conformation of the CTD which is additionally 
stabilized by hydrophobic interactions. Tyrosine and proline of the heptapeptide 
motif accommodate the CTD on the target surface. This binding mode would 
disregard an extended conformation of the CTD-peptide. The WW-domain of Pin1 
binds an entire signature motif of the CTD as an extended coil, with both 
phosphoserine/proline peptide bonds in the trans configuration (Verdecia et al., 
2000). 
In contrast with this published report, I was unable to obtain an appropriate 
'pattern' of amino acid residues involved in binding or deduce the cis-trans 
isomerization state of the CTD peptide. In my case, the model of electrostatic 
anchors would be tantalizing and indeed explain partially, why at least two repeats 
are necessary to observe binding between the SRI-domain and a CTD peptide and 
concomitantly only slight conformational changes are observed in the SRI domain-
phosphopeptide structure. As already stated in chapter 6.6, preliminary 
assignments indicate that one of the tyrosine side chains is in proximity of residues 
A662 and V666 in region 1 (Figure 26 C, Figure 29 B). Further examination of 
isotope-filtered experiments and a 3D 13C-edited NOESY implies an interaction 
between the same tyrosine and an unknown lysine residue. Owing to the high 
content of lysines, the resulting cross peaks were not well dispersed and a complete 
assignment of these residues was impaired. In addition, NOEs between a peptide 
proline and an isoleucine of the SRI domain could be observed but not assigned. 
The obstacle that the peptide was not labeled, prevented detailed characterization 
of the SRI domain/peptide interface in my hands. But the present work indicates a 
new fold of the SRI domain which contributes to the exploitation of CTD recognition 
modes.  
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Chapter III:  Materials and Methods 
7 GENERAL METHODS 
7.1 Bacterial strains 
Strain Description Source or 
reference 
DH5α F–φ80dlacZΔM15 Δ (lacZYA–argF) U169 
recA1 endA1 hsdR17(rk–, mk+) phoA 
supE44 λ– thi–1 gyrA96 relA1 
Woodcock et 
al., 1989 
XL-1 blue recA1 endA1 gyrA96 thi–1 hsdR17 supE44 
relA1 lac [F'proAB lacIqZΔM15 Tn10 (Tetr)] 
Stratagene 
BL21 (DE3)-RIL E. coli B F– ompT hsdS(rB– mB–) dcm+ Tetr 
gal λ (DE3) endA Hte [argU ileY leuW Camr] 
Stratagene 
BL21 (DE3) pLysS F– ompT hsdSB(rB–mB–) gal dcm (DE3) 
pLysS (CamR) 
Stratagene 
7.2 Plasmids 
# Name Protein 
segment 
Vector Restriction 
sites 
Affinity 
tag 
Expression 
1 variant1 Spt5 283 – 620 pET21b1 NdeI/NotI His6 low and 
degradation 
2 variant2 Spt5 380 – 620 pET21b1 NdeI/NotI His6 8 mg/ml 
3 variant3 Spt5 283 – 849 pET21b1 NdeI/NotI His6 low and 
degradation 
4 variant4 Spt5 380 – 849 pET21b1 NdeI/NotI His6 7.5 mg/ml 
5 variant5 Spt5 283 – 874 pET21b1 NdeI/NotI His6 degradation 
6 variant6  Spt5 380 – 874 pET21b1 NdeI/NotI His6 12 mg/ml  
7 variant7 Spt5 443 – 849 pET21b1 NdeI/NotI His6 low 
8 variant8 Spt5 529 – 849 pET21b1 NdeI/NotI His6 low 
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9 variant9 Spt5 283 – 543 pET21b1 NdeI/NotI His6 not  tested 
10 Spt4 Spt4 1 – 102 pET21b1 NdeI/NotI His6 good 
n. d.2 
11 complex Spt5 283 – 849 
Spt4 1 – 102 
pET24d3 NdeI/NotI 
NheI/EcoR I 
His6 
GST 
good 
n. d.2 
12 bicistron Spt5 283 – 849 
Spt4 1 – 102 
pET21b1 NheI/NotI His6 1 mg/ml 
13 Rpb4 Rpb4 1 – 221 pET21d3 BamHI/NcoI no tag not tested 
14 fusion15 Spt4 1 – 102 
Rpb7 1 – 107 
pET21b1 NdeI/NotI His6 Good 
n. d.2 
15 fusion13 Spt4 1 – 102 
Rpb7 1 – 107 
pET21b1 NdeI/NotI His6 10 mg/ml 
16 SRI_X1 SRI 543 – 733 pET21b1 NdeI/NotI His6 43 mg/ml 
17 SRI_X2 SRI 581 – 733 pET21b1 NdeI/NotI His6 not tested 
18 SRI_X3 SRI 618 – 733 pET21b1 NdeI/NotI His6 71 mg/ml 
19 SRI_X4 SRI 543 – 719 pET21b1 NdeI/NotI His6 not tested 
20 SRI_X5 SRI 581 – 719 pET21b1 NdeI/NotI His6 24 mg/ml 
21 SRI SRI 619 – 720 pET9d4 NcoI/Acc65I His6 3 – 7 mg/ml 
22 SRI M SRI 624 – 705 pET24d3 Acc65I/NotI His6 not tested 
23 SRI N aa 624 – 707 pET24d3 Acc65I/NotI His6 6 mg/ml 
24 SRI O aa 624 – 709 pET24d3 Acc65I/NotI His6 40 mg/ml 
25 SRI A aa 629 – 705 pET24d3 Acc65I/NotI His6 10.5 mg/ml 
26 SRI B aa 629 – 707 pET24d3 Acc65I/NotI His6 31 mg/ml 
27 SRI C aa 629 – 709 pET24d3 Acc65I/NotI His6 12.8 mg/ml 
28 SRI D  aa 632 – 705 pET24d3 Acc65I/NotI His6 not tested 
29 SRI E aa 632 – 707 pET24d3 Acc65I/NotI His6 13.3 mg/ml 
30 SRI F aa 632 – 709 pET24d3 Acc65I/NotI His6 11.5 mg/ml 
1 pET21b: ampicillin resistance 
2 not determined by Bradford 
3 pET24d and pET21d: kanamycin resistance 
4 pET9d: kanamycin resistance; His6 – ztag – TEVsite – protein sequence 
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7.3 Media1 
1 Lab protocols (http://www.embl.de/nmr/sattler/lab/) 
Luria Bertani medium 
1 % tryptone 
0.5 %  yeast extract 
0.5 % NaCl 
 
Medium A (per liter)1 
100 ml  M9 medium (10x) 
10 ml  trace elements solution (100x) 
20 ml  20 % (w/v) glucose or  
10 % (w/v) C13 glucose 
1 ml  1 M MgSO4 
0.3 ml  1 M CaCl2 
1 ml  biotin (1mg/ml) 
1 ml  thiamin (1mg/ml) 
 appropriate antibiotic(s) 
 
M9 medium (10x) (per liter)1 
60 g  Na2HPO4 
30 g KH2PO4 
5 g NaCl 
5 g 15NH4Cl 
 
Trace elements solution (100x) (per liter)1 
5 g  EDTA 
0.83 g FeCl3 x 6 H2O 
84 mg ZnCl2 
13 mg CuCl2 x 2 H2O 
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10 mg  CoCl2 x 6 H2O 
10 mg H3BO3 
1.6 mg MnCl2 x 6 H2O 
 
Stock solutions1 
1 M  CaCl2 (autoclaved) 
1 M  MgSO4 (autoclaved) 
20 % (w/v) Glucose (sterilized) 
1 mg/ml  biotin (filter sterilized) 
1 mg/ml  thiamin (filter sterilized) 
 
Supplements/Antibiotics 
100 mg/ml in H2O ampicillin 
50 mg/ml in H2O kanamycin 
50 mg/ml in H2O chloramphenicol  
1 M in H2O IPTG 
 
100 X proteaseinhibitor mix/ethanol 
3 mg/l leupeptin 
14 mg/l pepstatin A 
1.7 g/l PMSF 
3.3 g/l benzamidine 
 
Edman buffer  
200 mM Tris-HCl, pH 8.5  
2 % SDS 
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8 MICROBIOLOGICAL TECHNIQUES FOR EXPRESSION AND 
ANALYSIS OF RECOMBINANT PROTEINS 
8.1 Transformation  
A 50 μl aliquot of competent cells and plasmid DNA were thawed on ice. An amount 
of either 1 μl of plasmid DNA or 2 μl of PCR product were added to XL-1 blue or 
DH5α cells, respectively, and then incubated on ice for 20 minutes. Adjacent a 'heat 
shock' was performed at 42 °C for 60 seconds and the cells were again incubated 
on ice for 10 minutes. The cells were finally plated on LB agar plates containing 
either ampicillin (100 mg/ml) or kanamycin (50 mg/ml). The plates were incubated 
overnight at 37 °C.  
In the case of coexpression of two separate plasmids harbouring particular genes 
this protocol was also executed and the appropriate antibiotics considered. For 
isotopic labelling BL21 (DE3) pLysS cells were used for transformation and plated 
on LB agar plates containing chloramphenicol (50 mg/ml) and kanamycin 
(50 mg/ml). 
8.2 Gene expression in LB medium 
A fresh colony was picked within 24 h of transformation, and a starter culture was 
grown to late-log phase in 50 ml LB medium containing ampicillin or kanamycin. 
Two liter of LB medium supplemented with the appropriate antibiotics were 
inoculated and shaken (180 rpm) at 37 °C until the culture reached log phase (OD 
0.6 - 0.8). After cooling the E. coli suspension on ice IPTG at a 1 : 2000 ratio was 
added and the cells were grown over night at 18 °C. Cells were collected by 
centrifugation (5000 rpm, SLS6000 rotor) at 4 °C, subsequently suspended in lysis 
buffer (300 mM NaCl, 50 mM Tris pH 8.0, 5 % glycerol, 10 mM β-mercaptoethanol 
and 1 : 100 proteaseinhibitor mix) and frozen in liquid nitrogen before storage at  
-80 °C.  
8.3 Gene expression in minimal medium 
A fresh colony was picked within 24 h of transformation, and a starter culture was 
grown overnight in 20 ml medium A containing kanamycin (ratio 1 : 800) and 
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chloramphenicol (ratio 1 : 3333). This culture served as inoculum for two liter of 
medium A containing only kanamycin (1 : 1000) as antibiotic. To ensure better 
aeration only half a liter was filled in a 5 liter flask. The culture was shaken (200 
rpm) at 37 °C until the OD 600 was 0.6. After cooling on ice IPTG at a 1 : 2000 
ratio was added to induce over expression of the target protein. The cells were 
grown for 16 hours at 18 °C. Cells were collected by centrifugation (5000 rpm, 
SLS6000 rotor) at 4 °C, subsequently suspended in lysis buffer (300 mM NaCl, 50 
mM Tris pH 8.0, 5 % glycerol, 10 mM  β-mercaptoethanol, 1 : 100 proteaseinhibitor 
mix and frozen in liquid nitrogen before storage at -80 °C. 
8.4 Preparation of cleared E. coli lysates 
The first two steps in all protein isolation processes were cell lysis followed by 
clarification of the lysate to remove cell debris and nucleic acids. To release 
proteins from E. coli cells the frozen pellets were thawed in a 20 °C water bath and 
transferred to a glass beaker so that it is about half full. Samples were lysed on ice 
by sonication for 15 minutes with a Sonifier 450 rom Branson Utrasonics (Danbury, 
CT) using a duty cycle of 40 % and an output control setting of 4. Lysate 
clarification was achieved by centrifugation at 15 000 rpm for 20 minutes and the 
supernatant was collected for downstream steps of protein purification. 
8.5 Affinity chromatography 
In order to isolate a target protein from complex mixtures several chromatography 
techniques were applied. Practical aspects of performing a separation of each 
protein will be covered in the particular chapter, but an affinity chromatography 
step conducted each purification. The lysate, after clarification by centrifugation, 
was loaded on a self assembled Ni-NTA column (Quiagen) to retain 
complexes/proteins containing the His6-tag. 
8.6 Ion exchange chromatography 
The separation power of ion exchange chromatography is based on the fact that the 
relationship between net surface charge and pH is unique for a specific protein. 
According the results from ProtParam the appropriate Mono S HR 5/5 or Mono Q HR 
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5/5 (Amersham Biosciences) was chosen to separate molecules on the basis of 
differences in their net surface charge. The applied salt gradient ranged from 50 
mM to 1 M NaCl or (NH4)2SO4.  
8.7 Gel filtration 
Gel filtration separates molecules corresponding to differences in size as they pass 
through a gel filtration medium packed in a column. For purification purposes 
Superose6, Superose12 and Superdex75 columns (Amersham Biosciences) were 
utilised according to the instruction manuals.  
8.8 Limited proteolysis experiments 
A limited proteolysis approach and Edman sequencing were applied in order to 
determine the surface accessibility of conserved domains. Limited proteolysis of 
natively folded proteins occurs at flexible sites and therefore proteolytic probes can 
be used to pinpoint the sites of local unfolding in a protein chain. For trypsin 
treatment 1 μg of the protease was added to 20 μg to 50 μg of purified protein. 
Digests were done in the buffers used for gel filtration and supplemented with 
CaCl2 to a final concentration of 4 μM. The mixture was incubated at 37 °C and 
aliquots were removed at 1, 3, 10, 30 and 60 minutes. The reactions were stopped 
by the addition of SDS sample buffer and were heated immediately to 95 °C for 5 
min. All samples were analyzed by SDS-PAGE.  
8.9 Protein separation by SDS-PAGE  
Denaturing gel electrophoresis was adopted to separate complex protein mixtures 
into distinct bands on a gel. According to the discontinuous Laemmli system 
(Sambrook and Russel, 2001), ten gels were cast at once. The percentage of the 
gels (12 % -17 %) was defined by the size of the monitored proteins. The proteins 
were totally unfolded by adding β-mercaptoethanol to the SDS loading dye. Gels 
were then stained with Coomassie (SIGMA) solution and if required subjected to 
blotting procedures.  
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8.10 Blotting and Edman Sequencing 
For N-terminal sequencing, proteins in a gel cannot be sequenced but must be 
transferred out of the gel. After electrophoresis, the desired band of interest was 
excised and dried in a Speed Vac. Following, the gel piece was reswollen in 50 μl of 
Edman buffer. After setting up a gradient by addition of 200 μl of distilled water, a 
small piece of pre wet PVDF membrane was added to adsorb the protein. Once the 
solution began to turn blue from dye, methanol was added to a final concentration 
of 10 % and the transfer was complete when the membrane was blue. The 
procedure required two days incubation at room temperature. Finally the 
membrane was washed with 10 % methanol, dried and the strip was loaded into a 
PROCISE 491 sequencer (Applied Biosystems).  
8.11 Standard techniques 
Standard techniques in molecular biology such as isolation of DNA, restriction 
analysis, polymerase chain reaction (PCR), cloning of DNA, agarose gel 
electrophoresis etc. were performed essentially as described in Sambrook and 
Russel, 2001.  
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9 BIOINFORMATIC TOOLS AND SOFTWARE 
Alignments Multiple homologues sequence alignments were initially constructed 
using CLUSTAL-W (www.ebi.ac.uk/clustalw). The program ESPript (Easy 
Sequencing in PostScript - espript.ibcp.fr) was applied for the rapid visualization, 
via PostScript output, of the sequences aligned with CLUSTAL-W. 
Secondary structure prediction. Secondary structure prediction was done using 
the PredictProtein (http://cubic/bioc/columbia/edu/predictprotein.hmtl) secondary 
structure prediction surfer.  
Calculation of molecular weight, absorption coefficient and PI. Calculation of 
properties of the proteins which are important for the design of the purification 
strategy as the PI were determined using ProtParam. The absorption coefficients 
and molecular weights used for quantification were obtained form the same server 
(www.expasy.org/tools/protparam.html).  
Comparing protein structures. The Dali server (http://www.ebi.ac.uk/dali/) is a 
network service for comparing protein structures in 3D. By submitting the 
coordinates of a query protein structure to the server, Dali compares them against 
those in the Protein Data Bank. 
Figures. Most oft the molecular figures of RNAP II and the SRI domain were created 
using the program pymol (http://pymol.sourceforge.net/). Figure 26 is designed with 
MOLMOL (http://www.mol.biol.ethz.ch/groups/wuthrich_group/software).  
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10 RECOMBINANT SPT4-SPT5 PROTEINS AND ASSEMBLY OF 
THE ELONGATION CHECKPOINT COMPLEX – VARIOUS 
APPROACHES 
10.1 Single Spt5 variants 
10.1.1 Design and expression of different Spt5 variants 
For subcloning the nucleotide sequence of the different Spt5 protein variants into a 
bacterial expression vector, the forward primer were designed to create an NdeI 
site and to add the methionine codon before the first residue and the reverse 
primer were designed to create a NotI site without a stop codon. The desired 
nucleotide fragment was amplified by PCR using the appropriate oligonucleotides 
and the genomic S. cerevisiae DNA as a template, digested with NdeI and NotI, and 
subcloned into the NdeI and NotI restriction sites of pET21b (Stratagene) to 
construct the C-terminal six histidine (His6)-tagged expression plasmid. 
Corresponding to the NotI restriction site an AAALE linker between the Spt5 protein 
and the His6-tag was introduced. Transformation and expression of the different 
variants were carried out as mentioned. The cells were lysed by sonication, 
centrifuged, and the supernatant was loaded onto a Ni-NTA column (Quiagen), 
equilibrated with lysis buffer. The sample was eluted by a stepwise gradient from 
10, 20, 50 to 200 mM imidazole. The polypeptide compositions of the column 
fractions were monitored by SDS-PAGE. The recombinant His6-tagged polypeptides 
were recovered predominantly in the 50 mM or 200 mM imidazole fractions. Only a 
few of the expressed Spt5 variants could be further purified and yielded a 
reasonable amount of protein. Either they were prone to degradation or the 
expression level was low. Spt5 variant2, variant4 or variant6 were promising (see 
Diploma-thesis Vojnic, 2002).  
At best the 50 or 200 mM fractions were pooled and applied onto a MonoS column 
(HR 5/5) aquilibrated 50 mM (NH4)2SO4 (Table 5). The peak fractions were 
concentrated with an Amicon Ultracentrifuge device (cut off 10 kDa) and passed 
over a Superose6 gel filtration column. The final fractions were used for 
crystallization set-ups. 
C H A P T E R  I I I :   M A T E R I A L S  A N D  M E T H O D S  
77 
Table 5: Purification protocol of single Spt5 variants 
Step Buffer composition 
Lysis buffer 300 mM NaCl, 50 mM Tris-HCl pH 8, 5 % glycerin,  
10 mM β-mercaptoethanol, 1/100 proteaseinhibitor mix 
Wash solution  2 M NaCl 
Wash buffer  150 mM NaCl, 50 mM Tris-HCl pH 8, 5 % glycerin,  
50 mM imidazole, 10 mM β-mercaptoethanol 
Elution buffer 150 mM NaCl, 50 mM Tris-HCl pH 8, 5 % glycerin,  
200 mM imidazole, 10 mM β-mercaptoethanol 
MonoS 50 mM Hepes pH 7, 50 mM to 1 M (NH4)2SO4 
Superose 6  50 mM Hepes pH 7, 150 mM (NH4)2SO4 
10.2 Bicistronic Spt4-Spt5 variant3 pair 
10.2.1 Design and expression of bicistronic Spt4-Spt5 variant3 
The bicistronic Spt4-Spt5 variant3 pair was expressed from a pET21b vector. In this 
case, Spt4 was expressed as untagged full length protein and the adjacent Spt5 
variant was expressed as C-terminal His6-tagged fusion protein.  
To create this vector the gene sequences for the proteins were initially subcloned in 
another vector, kindly provided by S. Baumli. Spt4 was cloned via the restriction 
sites NheI and EcoRI into a pET24b derived vector containing an N-terminal GST-
TEV coding sequence in front of the multiple cloning site. A second ribosomal-
binding and multiple cloning site was introduced as described elsewhere (PhD-
thesis Baumli, 2005). The PCR Fragment of variant3 was inserted into the second 
ORF via its NdeI and NotI restriction sites and allowed the expression of a His6 
tagged variant of Spt5. This protein pair was unfortunately not straightforward to 
purify and hence for convenient handling the cassette containing the Spt4-Spt5 
variant3 pair was cut with NheI and NotI restriction enzymes and subcloned into an 
ampicillin resistant pET21b vector. The basic principles pertaining to the cloning 
procedure are outlined in Figure 31. The microbiological techniques for expression 
of recombinant Spt4-Spt5 variant3 proteins in E.coli were performed as described 
in chapter 8.  
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Figure 31. Flowchart of cloning procedure. 
10.2.2 Purification of Spt4-Spt5 variant3 
Thawed cells were lysed by sonication and centrifuged, and the supernatant was 
loaded onto a Ni-NTA column (Quiagen), which was equilibrated with lysis buffer. 
The sample was eluted stepwise from 20 to 50 mM imidazole and monitored by 
SDS-PAGE. The presence of Spt4 in the heterodimeric complex was verified by 
Edman Sequencing. Due to the aberrant retention volume of the complex on a size 
exclusion column and the associated loss of material, I performed the buffer 
exchange via a PD10 column. The column was equilibrated with the appropriate 
buffer containing 5 mM Hepes pH 7.5, 100 mM NH4(SO4)2, 10 μm ZnCl2, 5 mM DTT 
(Table 6). The protein amount was detected with Bradford Reagenz (biorad).  
Table 6: Purification protocol of Spt4-Spt5 variant3 complex 
Step Buffer composition 
Lysis buffer 300 mM NaCl, 50 mM Tris-HCl pH 8, 5 % glycerin,  
10 mM β-mercaptoethanol, 1/100 proteaseinhibitor mix 
Wash buffer  300 mM NaCl, 50 mM Tris-HCl pH 8, 5 % glycerin,  
10 mM β-mercaptoethanol, 20 mM imidazole 
Wash solution  2 M NaCl 
Elution buffer 300 mM NaCl, 50 mM Tris-HCl pH 8, 5 % glycerin,  
10 mM β-mercaptoethanol, 50 mM imidazole 
PD10 buffer 5 mM Hepes pH 7.5, 100 mM NH4(SO4)2, 10 μm ZnCl2,  
5 mM DTT 
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10.2.3 Assembly of RNAP II with Spt4-Spt5 variant3 
For assembly of an 'elongation checkpoint complex' consisting of the complete 
RNAP II and Spt4/Spt5 variant3 the procedure was as follows. Reconstitution of 12-
subunit RNAP II was initiated by thawing the ammonium sulphate pellet of the core 
polymerase at 4 °C and resuspending it in 150 μl PD10 buffer. Rpb4/Rpb7 were 
obtained frozen in RNAP II buffer (5 mM Hepes pH 7.25; 40 mM (NH4)2SO4; 
100 μm ZnCl2, 10 mM DTT), thawed, added to the core polymerase and incubated 
on a rotating wheel at 20 °C for 20 minutes. Subsequent purified Spt4-Spt5 
variant3 was combined with RNAP II and incubated at 4 °C for 1 hour. Both 10 fold 
excess of Rpb4/Rpb7 and Spt4-Spt5 variant3 were used. Meanwhile Superose6 was 
equilibrated with PD10 buffer and the peak fractions of the reconstitution reaction 
were monitored by 15 % SDS-PAGE.  
10.3 Rpb7/Spt4 fusion protein 
10.3.1 Design and expression of an artificial Rpb7/Spt4-Rpb4 complex 
According to the proposed homology between archeal subunit E" and Rpb7 from 
RNAP II and Spt4, a chimeric DNA comprising both sequences connected by a 
multiple glycine linker was introduced into a pET21b vector. This vector 
simultaneously permitted the bicistronic expression of Rpb4.  
Plasmids for expression of (full length) Rpb7-glycinelinker-Spt4 (full length) and 
Rpb4 (designated fusion protein complex) were constructed as follows. The Rpb7 
ORF was PCR amplified from genomic S. cerevisiae DNA as a template with an N-
terminal primer that added codons for an NdeI site (designated f1) and one C-
terminal primer that comprised the C-terminal region of Rpb7, codons for a 15G-
linker, and the N-terminal region of Spt4. Simultaneously, in a second PCR Spt4 
was amplified. An N-terminal primer was used, that added codons for the C-
terminus of Rpb7 to the 15G-linker and the Spt4 N-terminus (matching the DNA 
sequence added to Rpb7, above). The C-terminal primer appended codons for a 
NotI site (designated r2). The fusion was constructed by combining Rpb7-G15-
Spt4n with Rpb7c-G15-Spt4 PCR products for amplification with the N-terminal 
Rpb7 f1 primer and C-terminal Spt4 primer r2 followed by insertion as an NdeI-NotI 
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fragment into pET21b (adding a C-terminal hexahistidine tag to Spt4). The fusion 
generates a G15 linker between Rpb7 and Spt4, but due to unknown mechanisms 
another plasmid with a 13 glycine linker was also generated by accident. In parallel, 
the Rpb4 ORF was PCR amplified from genomic S. cerevisiae DNA as a template 
with an N-terminal primer that adds an N-terminal M codon and an NcoI site and a 
C-terminal primer that generates a BamHI site followed by insertion as an NcoI-
BamHI fragment into pET21d. This cassette was cut by BamHI-SphI restriction 
enzymes and the resulting BamHI-SphI fragment was inserted into the BglII-SphI 
site of pET21b (Rpb7-G15-Spt4) to generate pET21b (Rpb7-G15-Spt4/Rpb4). The 
heterologous protein expression occurred via two separate T7 promoters. For the 
sake of clarity, the primer sequences are shown in Table 7. The restriction sites are 
displayed in bold and the codons for the glycine linker are underlined. The basic 
principles pertaining to the cloning procedure are outlined in Figure 32.  
Table 7: Primer sequences 
Primer Sequence 
f1_NdeI GGGGGGGGGCATATGTTTTTTATTAAAGACCTTTCG 
r1 CATACAGGCTCTTTCACTAGACATACCGCCACCGCCACCGCCACCGCCAC
CGCCACCGCCACCGCCACCAATAGCACCCAAATA ATCTTC 
f2 GAAGATTATTTGGGTGCTATTGGTGGCGGTGGCGGTGGCGGTGGCGGT
GGCGGTGGCGGTGGCGGTATGTCTAGTGAAAGAGCCTGTATG 
r2_NotI GGGGGGGGGGCGGCCGCCTCAACTTGACTGCCATCCCTCGG 
f3_NcoI AGGTGCCATGGCGAATGTTTCTACATCAACC 
r3_BamHI CGCGGATCCCTAATAGAGTGTTTCTAGGTTTGAC 
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Figure 32. Cloning procedure (x = linker containing either 13 or 15 glycines). 
10.3.2 Purification of an artificial Rpb7/Spt4-Rpb4 complex 
The plasmids containing either fusion protein with a 13- or a 15-glycine linker were 
transformed in BL21(DE3) RIL (Stratagene) cells and expressed as described in 
chapter 8. Cells were disrupted by sonication and the lysate, after clarification by 
centrifugation at 15000 rpm, was loaded onto a one millilitre self assembled Ni-NTA 
agarose column (Quiagen). The His6-tagged Rpb7/Spt4 artificial complex should be 
retained onto the column and constitute a stochiometric subcomplex with Rpb4. In 
order to get rid of sticky DNA from the expression strain, the resin was washed with 
5 column volumes of 2 M NaCl. A second wash step included lysis buffer 
supplemented with 50 mM imidazol. The proteins were eluted with 5 ml lysis buffer 
containing 200 mM imidazol. Conditions for optimal purification steps were 
determined empirically. The eluted proteins were further purified by Mono S 
chromatography (5/5 Amersham). The column was pre-equilibrated with Mono S 
buffer containing 50 mM NaCl. A linear gradient was applied and the eluted proteins 
collected and concentrated by Amicon Ultra centrifugal devices (10 KDa molecular 
weight cut off). As a last purification step gel filtration was performed to exchange 
the protein into the running buffer and to separate last impurities from the desired 
proteins (Table 8). As judged by Coomassie staining, the stoichiometry of both 
recombinant proteins was given. 
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Table 8: Purification protocol of an artifical  
Rpb7/Spt4 and Rpb4 complex 
Step Buffer composition 
Lysis buffer 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 10 μm ZnCl2, 5 % 
glycerin, 10 mM β-mercaptoethanol, 1/100 proteaseinhibitor mix 
Wash solution  2 M NaCl 
Wash buffer  150 mM NaCl, 50 mM Tris-HCl pH 7.5, 5 % glycerin,  
10 mM β-mercaptoethanol, 50 mM imidazole 
Elution buffer 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 5 % glycerin,  
10 mM β-mercaptoethanol, 200 mM imidazole 
MonoS  50 mM Hepes pH 7.5, 50 mM to 1 M NaCl, 5 mM DTT 
Superose6  50 mM Hepes pH 7.5, 150 mM NaCl, 5 mM DTT 
10.3.3 Assembly of complex12 
Reconstitution of twelve-subunit RNAP II, which contained an artificial Rpb7/Spt4 
subunit homolog to archeal E/E", was performed at 4 °C. One ammonium sulphate 
pellet of endogenous ten-subunit RNAP II was thawed, the supernatant discarded, 
and the remaining pellet resuspended in 450 μl of Superose6 buffer. Addition of 
RNAP II to 5-fold excess of fusion protein occurred stepwise. Adjusting the volume 
to 500 μl was done prior to Superos6 gel filtration. The collected peak fractions 
were monitored by 15 % SDS-PAGE. 
10.4 Rpb7/Spt4 and Rpb4 complex plus Spt5 variant1 
10.4.1 Design and expression of complexes containing different Spt5 
variants 
The expression of all heterologues proteins was achieved by co-transformation of 
the plasmids harboring the components for establishing the elongation checkpoint 
complex. Initially, variant1, variant3 and variant5 were produced in E. coli as C-
terminal His6-tagged proteins simultaneously with the artificial fusion protein 
complex. Therefore the existing DNA sequences were cut out from the pET21b 
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vector by means of their NdeI/NotI restriction sites and ligated into a modified 
pET24d kanamycin resistant vector. The NcoI site was previously replaced by an 
NdeI site. The expression procedure was performed essentially as described earlier.  
10.4.2 Purification of Rpb7/Spt4 and Rpb4 complex plus Spt5 variant1 
Co-expression of Spt4/Rpb7/Rpb4 together with Spt5 variant1 seemed most 
promising concerning the stoichiometry of all components. The proteins were step-
eluted with 200 mM imidazole in lysis buffer (Table 9). The pooled fractions were 
applied onto a Mono Q column and eluted by a linear gradient, starting with 
150 mM NaCl. The peak fractions were visualised by Coomassie-staining and the 
stochiometric samples concentrated by Amicon Ultra centrifugal devices (100 KDa 
molecular weight cut off). For further experiments concentrated protein was stored 
as ammonium sulphate pellet. Hence, purified protein was precipitated after Mono 
Q with saturated ammonium sulphate, frozen in liquid nitrogen and stored at  
-80 °C.  
Table 9: Purification protocol of a complex comprising  
Rpb7/Spt4 and Rpb4 plus Spt5 variant1  
Step Buffer composition 
Lysis buffer 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 10 μm ZnCl2, 5 % 
glycerin, 10 mM β-mercaptoethanol, 1/100 proteaseinhibitor mix 
Wash solution  2 M NaCl 
Wash buffer  150 mM NaCl, 50 mM Tris-HCl pH 7.5, 5 % glycerin,  
10 mM β-mercaptoethanol, 50 mM imidazole 
Elution buffer 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 5 % glycerin,  
10 mM β-mercaptoethanol, 200 mM imidazole 
Mono Q 50 mM Bicine pH 8.5 @ 10 °C, 150 to 1 M NaCl, 5 mM DTT 
10.4.3 Assembly of complex13 
The RNAP II-Spt4/Spt5 complex was assembled by incubating core RNAP II 
(resuspended in 50 μl of 150 mM ammonium sulphate, 50 mM Hepes pH 7.5, 10 
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mM DTT) for 10 minutes at 4 °C with a 1.5 molar excess of Spt4/Rpb7/Rpb4-Spt5 
variant1, on hand in Mono Q buffer. This complex was transferred to a MembraSpin 
centrifugal concentrator (100 kDa cutt off) and the buffer adjusted to 150 mM 
ammonium sulfphate, 50 mM Hepes pH 7.5 and 10 mM DTT. The buffer exchange 
was achieved by diluting the concentrated sample several times with altogether two 
milliliter of the desired buffer and monitoring the conductivity.  
10.4.4 Assembly of 'elongation checkpoint complex' 
A DNA/RNA hybrid was annealed by mixing equimolar amounts of synthetic 
template DNA, non-template DNA and RNA oligonucleotides (biomers.net) in RNAse 
free TE buffer (Fluka) at a final concentration of 100 μM. The mixture was heated to 
90 °C in a thermoblock (preheated) and slowly cooled to 20 °C over night. All 
relevant steps for the assembly were done at 4 °C. Core RNAP II was resuspended 
in 50 μl of 150 mM ammonium sulphate, 50 mM Hepes pH 7.5, 10 mM DTT buffer 
and incubated with 100 pmol DNA/RNA hybrid for 15 minutes. An ammonium 
sulphate pellet of Rpb7/Spt4 and Rpb4 complex plus Spt5 variant1 was thawed, 
dissolved in assembly buffer (200 μl of 150 mM ammonium sulphate, 50 mM Hepes 
pH 7.5, 10 mM DTT) and followed by the incremental addition of RNAP II-DNA/RNA 
complex. After ten minutes of incubation the assembly reaction was transferred to 
a MembraSpin centrifugal concentrator (100 kDa cut off) and the buffer adjusted to 
150 mM ammonium sulfphate, 50 mM Hepes pH 7.5 and 10 mM DTT. The 
procedure was like the assembly of RNAP II-Spt4/Spt5 complex. Prior to the last 
cryo step, an additional amount of DNA/RNA hybrid was added to a final 
concentration of 2 µM in order to ensure full occupancy. 
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11 RECOMBINANT SRI DOMAIN VARIANTS AND PHOSPHO-
PEPTIDE STUDIES 
11.1 Design and cloning of different SRI domain variants 
For following crystallization set-ups DNA fragments comprising varying parts of the 
SRI domain were amplified by PCR and cloned into the NcoI/NotI sites of a pET24d 
(G. Stier/EMBL) vector containing an N-terminal His6-tag (as indicated in chapter 
7.2). For NMR spectroscopy the DNA fragment encoding for residues 620 – 719 was 
amplified by PCR and cloned via its NcoI/Acc65I sites into a modified pET9d vector 
(G. Stier/EMBL) that contained a TEV protease site directly after the N-terminal z-
tag and His6-tag.  
11.2 Purification of SRI domain variants 
11.2.1 Purification of pET24d expressed SRI domain variants for 
crystallization 
The cell lysate was applied to a His-select nickel column (Quiagen) and each protein 
eluted in 200 mM imidazole. Fractions containing the desired protein were pooled, 
diluted in the same volume of MonoS buffer without salt and applied onto a MonoS 
(Amersham) column. The final purification step comprised a Superdex75 gel 
filtration and the peak fractions were concentrated for crystallization (Table 10).  
Table 10: Purification protocol for crystallization set-ups 
Step Buffer composition 
Lysis buffer 300 mM NaCl, 50 mM Tris-HCl pH 7.5, 5 % glycerin,  
10 mM β-mercaptoethanol, 1/100 proteaseinhibitor mix 
Wash solution  2 M NaCl 
Wash buffer  300 mM NaCl, 50 mM Tris-HCl pH 7.5, 5 % glycerin,  
10 mM β-mercaptoethanol, 50 mM imidazole 
Elution buffer 300 mM NaCl, 50 mM Tris-HCl pH 7.5, 5 % glycerin,  
10 mM β-mercaptoethanol, 200 mM imidazole 
Mono S 30 mM Mes pH 6.5, 50 mM to 1 M NaCl  
Superdex75 20 mM Mes pH 6.5, 175 NaCl, 2 mM DTT 
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11.2.2 Purification of pET9d expressed SRI domain for NMR spectroscopy 
Cell lysates were subjected to affinity chromatography on a first Ni-NTA column 
(Quiagen), followed by cleavage of the hexahistidine tag with TEV protease and 
dialysis overnight. The tag and the His6-tagged protease were removed on a second 
Ni-NTA column. The pooled fractions were diluted carefully with MonoS buffer 
(without salt) until the conductivity was around 150 μS/cm. DNA was removed by 
cation exchange chromatography (MonoS, Amersham). After gel filtration the 
sample was dissolved in buffer containing 20 mM sodium phosphate pH 6.5, 200 
mM NaCl and 2 mM DTT (Table 11). Edman sequencing of the protein confirmed the 
presence of four additional residues (GAMG) at the N-terminus, which resulted from 
the cloning strategy. 
Table 11: Purification protocol for NMR spectroscopy 
Step Buffer composition 
Lysis buffer I 300 mM NaCl, 50 mM Tris-HCl pH 8, 5 % glycerin,  
10 mM β-mercaptoethanol, 1/100 proteaseinhibitor mix 
Wash solution I 2 M NaCl 
Wash buffer I 300 mM NaCl, 50 mM Tris-HCl pH 8, 5 % glycerin,  
10 mM β-mercaptoethanol, 20 mM imidazole 
Elution buffer I 300 mM NaCl, 50 mM Tris-HCl pH 8, 5 % glycerin,  
10 mM β-mercaptoethanol, 200 mM imidazole 
Dialysis buffer 500 mM NaCl, 50 mM Tris-HCl pH 8, 2 mM DTT 
Lysis buffer II 500 mM NaCl, 50 mM Tris-HCl pH 8,  
10 mM β-mercaptoethanol, 
Elution buffer II 500 mM NaCl, 50 mM Tris-HCl pH 8, 30 mM imidazole,  
10 mM β-mercaptoethanol, 
Mono S 30 mM Mes pH 6.5, 50 mM to 1 M NaCl, 2 mM DTT 
Superdex75 20 mM sodium phosphate pH 6.5, 200 mM NaCl, 2 mM DTT 
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11.3 Phosphopeptide interaction studies 
11.3.1 Crystallization set-ups 
The phospho-CTD peptides used for binding experiments were chemically 
synthesized [three-repeat peptide, SPS-YEPTEPS-YEPTEPS-YEPTEPS, E= glutamate 
mimics phosophoserine (http://www.jerini.com/); two-repeat peptide, SPS-
YSPTpSPS-YpSPTpSPS, pS=phosphoserine (http://www.anaspec.com/)]. For 
crystallization set-ups 1.25-fold molar excess of peptide was co-crystallized with 
the appropriate SRI domain protein.  
11.3.2 NMR-titration 
The phospho-CTD peptides used for binding experiments were chemically 
synthesized [one-repeat peptide, YpSPTpSPS (G. J. Arnold; gene center); two-
repeat peptide, SPS-YpSPTpSPS-YpSPTpSPS, pS=phosphoserine 
(http://www.anaspec.com/)]. For NMR titration, increasing amounts of the CTD 
peptide were added to a 0.4 mM solution of 15N,13C-labeled SRI domain up to a 
1.25-fold molar excess. Chemical shifts were monitored in 2D 1H,15N HSQC 
experiments. The lyophylized, synthetic equivalents of the CTD were dissolved 20 
mM sodium phosphate pH 6.5, 200 mM NaCl, 2 mM DTT. 
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12 STRUCTURE DETERMINATION BY SOLUTION NMR 
12.1 NMR data acquisition 
NMR spectra were acquired at 292 K on Bruker DRX500, DRX600, or DRX900 
spectrometers with cryogenic triple resonance probes. Spectra were processed with 
NMRPipe (Delaglio et al., 1995) and analyzed using NMRVIEW (Johnson and 
Blevins, 1994). 
12.2 Backbone assignment of chemical shifts 
A combined set of heteronuclear multidimensional NMR experiments were recorded 
for the assignment of the 1H, 13C, and 15N chemical shifts of uniformly labelled 
protein. The resonance assignment strategy involved the concerted use of four 3D 
triple-resonance experiments [HN(CO)CA, HNCA, CBCA(CO)NH and 13C-resolved 
three-dimensional NOESY]. The central feature of this policy was the concurrent 
assignment of both backbone and side-chain aliphatic atoms, which was critical for 
overcoming ambiguities in the assignment process. The combination of the 3D 
experiments HNCA and HN(CO)CA was used to establish backbone sequential 
connectivities by connecting the resonance frequencies of spins with those of 
preceding residues. The CBCA(CO)NH experiment was used to extend the 
connectivities from the backbone to Cβ as the chemical shifts of the side-chain 
carbons are characteristic for the amino acid type. This information can be utilized 
to position sequentially connected fragments within the amino acid sequence 
(Sattler et al., 1999). 
12.3 Structure calculation and determination 
Distance restraints were derived from 2D NOESY (Nuclear Overhauser effect 
spectroscopy) and 15N- or 13C-resolved 3D NOESY. Restraints for the backbone 
dihedral angles Φ and Ψ were derived from TALOS (Cornilescu et al., 1999). The 
protection of amide protons against chemical exchange was identified from 1H/15N 
correlation experiments after dissolving of lyophilized protein in 100 % D2O. 
Analyzing 15N relaxation parameters is a powerful means of characterizing protein 
backbone dynamics and therefore three sets of relaxation measurements (NOE, T1 
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and T2) were performed. 15N relaxation (T1, T2) and heteronuclear 1H-15N NOE 
was measured on a 15N-labelled protein sample at 292 K (Farrow et al., 1994). The 
experimentally determined distance and dihedral restraints (Table 4, Figure 26 C) 
were applied in a simulated-annealing protocol using ARIA (Linge et al., 2001) and 
CNS (Bruenger et al., 1998). NOEs were manually assigned and distance 
calibrations were performed by ARIA. The final ensemble of NMR structures was 
refined in a shell of water molecules (Linge et al., 2003). Structural quality was 
analyzed with PROCHECK (Laskowski et al., 1996).  
12.4 NMR titration experiment – 1H-15N HSQC 
The 1H-15N HSQC (heteronuclear single quantum coherence) NMR experiment is a 
two dimensional experiment in which each amino acid residue (except for proline) 
in a given protein is described by one peak in the spectrum. The chemical shift of a 
peak at (ω1, ω2), where ω1 and ω2 are the amide 15N and 1H shifts, respectively, 
depends from the chemical surrounding of the amino acid amide group in the 
protein. In addition, the side chain amides of glutamine and asparagine are 
represented in the spectrum. A folded protein structure will generally produce a 1H-
15N HSQC spectrum with a broad distribution of well separated signals. Changes in 
the environment of a spin due to binding of a ligand give rise to chemical shift 
changes in the NMR spectrum. These changes are expected to be largest near the 
binding site and the interface of a protein with a ligand can be easily mapped.  
12.5 Isotope filtering experiments 
To understand the function of biological macromolecules, it is important to 
illuminate the molecular crosstalk between these molecules. For studying the 
structures of molecular complexes by NMR spectroscopy, it is essential to 
distinguish between intra- and intermolecular NOEs. This task can be achieved by 
heteronuclear filtered NOE experiments performed on a sample of a complex 
consisting of differentially labeled molecules. In the binary complex consisting of 
13C, 15N-labeled SRI domain (A) and unlabeled peptide (B), four kinds of NOE cross 
peaks can be observed (Table 12). 
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Table 12: NOE cross peaks observed in complexes 
intramolecular: intermolecular: 
A – A: 1H-(13C,15N) – 1H-(13C,15N) A – B: 1H-(13C,15N) – 1H-(12C,14N) 
 B – B: 1H-(12C,14N) – 1H-(12C,14N) B – A: 1H-(12C,14N) – 1H-(13C,15N) 
The connectivity of protons to the heteronuclei 13C and 15N can therefore be used 
to separate intra- and intermolecular NOEs and the intramolecular NOEs of A and B 
(Sattler et al., 1999). For that purpose, a 2D ω2-13C,15N-filtered NOESY was 
acquired to examine especially the intermolecular NOEs between peptide and SRI 
domain.  
12.6 TOCSY experiments 
In general, the HCCH-TOCSY (Total correlation spectroscopy) experiment correlates 
all aliphatic 1H and 13C spins within residues, and is used to assign aliphatic 1H and 
13C resonances and connect the side-chain chemicals shifts with the backbone 
assignment (Teng, 2005). Here, the scalar couplings observed in different TOCSY 
experiments (mixing time 30 or 60 ms) were used to correlate the spins within the 
spin system of the 'free' and unlabeled peptide. The measurements were either 
performed in the same buffer conditions as for the NMR-titration experiment (20 
mM sodium phosphate pH 6.5, 200 mM NaCl, 2 mM DTT/2 mM peptide 
concentration) or in 100 % D2O (0.4 mM peptide concentration).  
12.7 ROESY experiments 
ROSY (Rotating-frame Overhauser effect spectroscopy) is an experiment in which 
homonuclear NOE effects are measured under spin-locked conditions. Both ROESY 
and NOESY experiments utilize the dipolar interaction in the form of cross 
relaxation to correlate spins that are close in distance. In the case of small and 
medium size molecules, the NOESY experiment is limited as the NOE enhancement 
is close to zero. The ROESY experiment has been developed to overcome this 
problem (Bax and Davis, 1985). The pulse sequence in this experiment is similar to 
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TOCSY although the cross-peaks of a ROESY spectrum have an opposite phase to 
those in the TOCSY spectrum (Teng, 2005).  
13 PROTEIN CRYSTALLOGRAPHIC METHODS 
13.1 Crystallization and crystal freezing 
Crystals of RNAP II in conjunction with varying Spt4-Spt5 proteins were obtained at 
20 °C with the hanging drop vapor diffusion method using 24 well plates. The 
applied buffer solutions varied in the concentration of one component (see Table 1) 
and thereby narrowed the variation space of the crystallization parameters 
involved. The crystallization droplets contained the appropriate complex solution 
mixed with the well solution either in a 1 : 1 or 2 : 1 ratio. Crystals were obtained 
mostly after one week. For cryo-protection, crystals were stabilized in six steps by 
replacing the crystallization condition against mother solution containing an 
increasing amount of glycerin until the final concentration of 22 % was reached. 
The crystals were stored in the last cryo-solution in a styropor box over night at 
8 °C, and then flash frozen in liquid nitrogen.  
For crystallization set-ups of the SRI domain variants, I embarked on the 
established sparse matrix strategy, (Jancarik and Kim, 1991) using the 
commercially available screens mentioned in chapter 6.1 – Table 3. Sitting drops 
were performed by the crystallization robot Hydra I.  
13.2 Data collection and structure determination 
All diffraction data were collected with an increment of 0.5 degree per image at the 
beamline X06SA at the Swiss Light Source, Villigen, Switzerland and processed with 
DENZO and SCALEPACK (Otwinowski and Minor, 1996). Crystal structures were 
solved at 4.0 – 4.5 Å resolutions by molecular replacement with the program 
PHASER (Storoni et al., 2004), using the complete RNAP II elongation complex 
(Protein Data Bank ID: 1Y1W) as a search model. The model was improved with 
iterative cycles of refinement with CNS (Bruenger et al., 1998).  
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